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Abstract 
Clear cell renal cell carcinoma (ccRCC) is characterized by Von Hippel-Lindau (VHL)-
deficiency, resulting in pseudohypoxic, angiogenic and glycolytic tumours.  Hydrogen sulfide 
(H2S) is an endogenously-produced gasotransmitter that accumulates under hypoxia and has 
been shown to be pro-angiogenic and cytoprotective in cancer.  It was hypothesized that H2S 
levels are elevated in VHL-deficient ccRCC, contributing to survival, metabolism, and 
angiogenesis.  Using H2S-specific probes, it was found that H2S levels were higher in VHL-
deficient ccRCC cell lines compared to cells with wild-type VHL.  Inhibition of H2S-
producing enzymes could reduce the proliferation, metabolism and survival of ccRCC cell 
lines, as determined by live-cell imaging, XTT/ATP assay, and flow cytometry, respectively.  
Using the chorioallantoic membrane angiogenesis model, it was found that systemic 
inhibition of endogenous H2S production was able to decrease vascularization of VHL-
deficient ccRCC xenografts.  Endogenous H2S production is an attractive new target in 
ccRCC due to its involvement in multiple aspects of disease. 
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1. Introduction 
1.1 Renal Cell Carcinoma (RCC) 
As with other cancers, kidney cancer can be categorized into multiple sub-types.  The 
most prevalent form of kidney cancer is known as renal cell carcinoma (RCC) and 
accounts for 80-90% of kidney cancer cases and 2-3% of all cancer cases (1).  RCC arises 
as a result of mutations to the epithelial cells of nephrons – the functional units of the 
kidney.  Increasing incidence rates for RCC have been reported over the last few decades, 
and this has been attributed to popular usage of CT and ultrasound imaging for other 
conditions (2).  Some studies suggest that increasing incidence of RCC risk factors like 
diabetes, hypertension and obesity may also be responsible for the increasing prevalence 
of RCC, though these conditions have not been established as true etiological factors of 
RCC (3-7).  Despite the increase in incidental detection of RCC and timely removal of 
the primary tumour, the cancer-specific mortality rate of RCC remains high at 30-40% 
(2).  This high mortality rate is due to the high likelihood – approximately 20-30% – that 
the disease has already metastasized at the time of detection (2).  Unfortunately, 
metastatic RCC (mRCC) has proven to be highly resistant to both chemotherapy and 
radiation therapy, and this resistance contributes to the high mortality rates observed (8).  
While it is true that novel growth-targeting therapies offer improvements in overall 
survival (OS) and progression-free survival (PFS), these therapies do not offer a cure for 
the disease (1). 
RCC can be further sub-divided into various histotypes based on tumour morphology, 
genetic signature, and clinical manifestation.  The area of the nephron from which the 
tumour arises (proximal tubule, distal tubule, collecting duct, etc.) also plays a role in the 
classification of RCCs (9).  Whether sporadic or inherited, genetic mutations in RCC 
often affect pathways involved in oxygen, nutrient, or energy sensing and for this reason 
RCC is often described as a metabolic disease (9,10).  In today’s clinical landscape of 
targeted therapies, identifying key targets within these metabolic pathways is essential 
(1,11). While most subtypes of RCC seem to subvert cellular metabolic pathways to their 
advantage, the specific pathways that are disrupted in each subtype, and indeed in each 
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patient, varies widely (12).  Identifying pathways that are commonly disrupted in RCC 
and developing therapies that target these pathways has proven to be an effective 
treatment strategy in RCC in that they improved PFS when compared to chemotherapy 
and radiation therapy (12). 
1.1.1 Clear Cell RCC and Von Hippel-Lindau 
The most common histotype of RCC is the clear cell histotype (ccRCC) and accounts for 
75-80 % of all RCC cases (2).  The characteristic “clear” cytoplasm of these cancer cells 
is due to increased production and accumulation of deposits containing cholesterol esters, 
fatty acids, and glycogen which makes histological identification relatively easy.  While 
the exact mechanisms that lead to accumulation of these lipid deposits are still being 
investigated, we do know that a crucial step in this process is inactivation of a key tumour 
suppressor – the Von Hippel-Lindau (VHL) tumour suppressor (13,14).  VHL is an E3 
ubiquitin ligase that is crucial in targeting certain cellular proteins for proteasomal 
degradation in response to changing cellular conditions, and is inactivated in the large 
majority (90%) of ccRCC tumours (1,15).  When VHL is expressed in its wild-type form 
(VHL WT), it is involved in regulating a number of homeostatic pathways, including the 
metabolism and storage of macromolecules.  Cells that lack a functional copy of VHL 
(VHL-deficient) lose control of multiple metabolic pathways, leading to decreased β-
oxidation of fatty acids, increased synthesis of fatty acids and glycogen, and increased 
storage of fatty acids and esterified cholesterol (13,14).  The end result is a cell with 
clear, lipid-filled cytoplasm. 
While VHL inactivation and subsequent lipid accumulation may prove to be an 
etiological link between established risk factors of ccRCC and the disease itself, VHL 
deficiency plays other, more significant roles in cancer initiation and progression.  The 
best understood function of VHL is as a master regulator of the hypoxic response, and 
key tumour suppressor for many cells in the body (16).  In combination with hypoxia-
inducible factors (HIFs) and prolyl hydroxylase (PHD), VHL ultimately controls the 
expression of genes that allow cells to cope with the harmful effects of hypoxia, and 
restore cellular oxygenation.  HIFs are heterodimeric transcription factors composed of α 
(HIF-α) and β (HIF-β) subunits that promote the transcription of genes containing 
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hypoxia response elements (HREs).  PHD is an enzyme that hydroxylates proline 
residues on various proteins, but only in the presence of an essential cofactor – oxygen.  
As mentioned previously, VHL is an E3 ubiquitin ligase that specifically recognizes and 
binds to proteins with hydroxylated proline residues and targets them for proteasomal 
degradation through ubiquitination.  HIF-β subunits are not a substrate for hydroxylation 
by PHD, and therefore are consistently present under normoxic and hypoxic conditions.  
HIF-α subunits on the other hand are hydroxylated by PHD and targeted for degradation 
by VHL under normoxic conditions to ensure that hypoxia response genes are not 
expressed unnecessarily (17).  However when oxygen is absent during periods of 
hypoxia, PHD cannot hydroxylate HIF-α residues, allowing them to escape recognition 
by VHL, form a functional heterodimer with HIF-β, translocate to the nucleus, and 
initiate the hypoxic response (16). 
Genes containing HREs include vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), transforming growth factor alpha (TGF- α), glucose 
transporter-1 (GLUT-1), matrix metalloproteinases (MMPs), carbonic anhydrase IX, 
erythropoietin, cyclooxygenase-2, c-MYC, cyclin D1, and many more (18).  Induction of 
many of these genes through the VHL/HIF pathway is a useful means of minimizing 
injury and re-establishing tissue oxygenation during periods of hypoxia that occur 
following disruptions in blood supply (19).  However, when these genes are aberrantly 
expressed under normoxic conditions as a result of VHL inactivation, the resulting cells 
are hyperproliferative, invasive, angiogenic and cell death-resistant as a result of their 
perceived hypoxia, or pseudohypoxia (Figure 1) (14).  It is this pseudohypoxia, as a result 
of VHL inactivation, that plays the largest role in the initiation and progression of 
ccRCC. 
As a tumour suppressor, VHL only loses its function after both genetic copies of the gene 
have been lost as a result of deletion, silencing via methylation, or some other form of 
mutation (15).  In other words, spontaneous ccRCC often only occurs when an already 
heterozygous cell loses its functional genetic copy of VHL following a “second hit,” 
resulting in complete loss of protein function.  Loss of VHL function is common in many 
cancers, but it was first discovered to have tumourigenic consequences in a rare 
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autosomal-dominant condition known as VHL Disease (20).  The majority (80%) of 
patients afflicted with VHL disease inherit a mutant copy of VHL from one of their 
parents, and following mutation to the second copy begin to develop cysts and tumours of 
the kidney (ccRCC), pancreas, retina, and other areas of the central nervous system (16).  
It was from studying this rare hereditary disease that the tumour suppressive role of VHL 
in ccRCC and other cancers was elucidated (21). 
Clearly VHL loss of function is an important step in neoplastic and malignant 
transformation.  However this, by itself, is neither necessary nor sufficient for the 
formation of ccRCC tumours (22,23).  Furthermore, there has been no conclusive 
evidence which suggests that VHL mutation status – regardless of its overall effect on 
VHL function – holds any value as a biomarker or prognostic indicator (16).  It is now 
generally accepted that classification of ccRCC tumours as VHL-deficient versus VHL 
WT is not sufficient.  VHL-deficient tumours can be further subdivided according to the 
degree to which they express the two major HIF-α isoforms (HIF-1α and HIF-2α).  There 
are VHL-deficient tumours which aberrantly express increased levels of HIF-1α and HIF-
2α (H1H2), and those which express increased levels of HIF-2α only (H2) (24).  Several 
studies have highlighted that HIF-1α and HIF-2α have very different effects on gene 
transcription in ccRCC (25), and most suggest that VHL-deficient H2 tumours are more 
proliferative and angiogenic than their H1H2 counterparts (26,27). 
The increased proliferation of H2 ccRCC cell lines and tumours is in part due to 
autocrine growth signaling that occurs through HIF-2α, TGF-α and the epidermal growth 
factor receptor (EGFR) that binds TGF-α (26,28,29).  Furthermore, the activity of 
oncoproteins such as c-MYC and cyclin D1 are upregulated by HIF-2α (24,26), whereas 
the activity of pro-apoptotic genes such as BNip3 are upregulated by HIF-1α (26).  
Angiogenesis in pseudohypoxic ccRCC cells also appears to be driven by induction of 
VEGF through HIF-2α, and loss of HIF-1α may actually exacerbate this process due to a 
loss of feedback inhibition that is normally mediated by HIF-1α (26,27).  Not only is the 
H2 phenotype more aggressive than the H1H2 phenotype, but it may actually be more 
common in VHL-deficient ccRCC tumours as a result of a greater likelihood of HIF-1α 
undergoing degradation than HIF-2α (18).  It has even been suggested that H2 tumours 
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are derived from H1H2 tumours and that loss of HIF-1α is a key step in ccRCC tumour 
progression (9,30). 
With HIF-α transcription factors identified as mediators of ccRCC progression, the 
development of therapies is now focused on inhibiting the pathways that the downstream 
effectors of HIF-1/2 α (VEGF, TGF-α, etc.) feed into.  The development of this targeted 
therapy approach has improved PFS of patients with ccRCC and represents a small 
victory in cancer treatment (31).  However, these therapies are not curative, and are only 
effective for a matter of months before the cancer becomes resistant to them. 
1.1.2 Past and Present (cc)RCC Therapies 
First-line treatment of localized RCC, regardless of histotype, is usually surgery seeing as 
it is the only curative therapeutic approach (32).  When determining the extent of renal 
mass to be excised, a number of factors must be evaluated.  The staging of the tumour 
according to size and presence/absence of local/distant metastases (TNM staging) is the 
first to be evaluated.  Patients with T1 tumours (<7 cm, limited to kidney) are often good 
candidates for a partial nephrectomy (PN), a procedure in which only the tumour and 
immediate surrounding area of the kidney are removed (33).  Experienced centers may 
even perform this PN laparoscopically instead of opting for traditional open surgery.  PN 
is the preferred course of treatment where the tumour is affecting a solitary functional 
kidney or the patient is in overall poor condition.  In these cases, sparing as much 
functional tissue as possible is a priority and active surveillance may be preferred to 
surgery.  Removal of the entire kidney, or radical nephrectomy (RN), is recommended in 
cases of locally advanced tumour growth or unfavourable tumour location.  RN is often 
performed laparoscopically for T2 tumours (7-10 cm, limited to kidney), however open 
surgery is recommended for T3 and T4 tumours which involve local and distant 
metastases (32). 
There are additional, minimally invasive first-line therapies for patients with localized 
disease who may not be good surgical candidates.  RCC tumours have been shown to 
respond to various ablation therapies such as percutaneous radiofrequency ablation, 
microwave ablation, laser ablation, cryoablation and high-intensity focused ultrasound 
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ablation.  The local progression rates for these therapies are often higher than those of 
partial and radical nephrectomy, however they are useful for treatment of incidental 
lesions in the elderly, multiple bilateral tumours, recurring small renal masses, and 
patients at risk of losing all renal function following nephrectomy (32).  In general, 
treatment of localized RCC with surgery is good, but it is not perfect.  The 5-year 
survival rate of patients with stage I disease (T1, N0, M0) is >90%.  However relapse 
occurs within 5 years of surgery for patients with stage II (T2, N0, M0) or III (T3, N0, 
M0; T1-3, N1, M0) disease (34).  Aggravating this situation is the fact that we have yet to 
identify adjuvant therapies that might manage this risk of relapse (35,36).  Managing 
intermediate/high-risk RCC in its early stages is just as important as targeting stage IV 
mRCC, which presents its own set of challenges (36). 
When possible, removal of metastases through surgery (metastectomy) can improve 
prognosis if all metastatic lesions are completely removed (37).  However, systemic 
therapy is often required in cases where metastases are unresectable and/or burden of 
disease is too great (32).  Chemotherapy and radiation therapy have, unfortunately, 
proven to be ineffective for treatment of mRCC, regardless of histotype.  Poor response 
rates – ranging from 0-14% – to a wide range of cytotoxic agents have been well-
documented and are attributed to expression of multi-drug resistance gene 1 and its 
protein product P-glycoprotein (8).  The molecular mechanisms conferring resistance to 
radiation therapy are less well understood, however there have been links drawn to 
increased expression of HIF-2α and survivin (38,39).  While investigations into these 
therapeutic immunities were being made, it was found that immune-based therapies were 
a viable treatment option for mRCC (2). 
Alongside melanoma, RCC is considered to be one of the most immunogenic of all 
human malignancies.  This is based on high tumoural infiltration of cytotoxic T-cells and 
other immune cells that can recognize tumour-associated antigens, the occurrence of 
RCC in patients receiving immunosuppression, and rare observation of spontaneous 
metastatic regression (40).  Of the wide array of immunotherapies investigated, cytokine-
based therapies such as high-dose interleukin-2 (IL-2) and interferon-alpha (IFN-α) have 
proven to be most effective and were recommended for treatment of mRCC prior to the 
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advent of targeted therapies.  Some argue that such therapies are indeed still relevant for 
treatment of mRCC given their durable responses in a subset of patients, which is an area 
where newer therapies fall short (41,42).  However, finding predictive biomarkers that 
can identify this subset of patients is a priority given the fact that associated toxicities of 
cytokine therapy are generally higher grade when compared to targeted therapies (42).  
First-line treatment of low-risk mRCC with IFN-α may also be just as effective as the 
currently recommended first-line targeted therapy sunitinib, but at significantly lower 
cost it could improve economic efficiency (41).  Combination treatments consisting of 
cytokine/targeted therapy are also being investigated and present the possibility of 
durable responses in a larger proportion of patients (36,41,42). 
From increased understanding of the molecular pathways that are active in RCC, 
specifically ccRCC, have emerged therapies that hone in on these pathways.  These 
targeted therapies come in two forms: small molecule inhibitors (SMIs), and monoclonal 
antibodies (mAbs).  Since 2007, 8 targeted therapies – sorafenib, sunitinib, temsirolimus, 
bevacizumab, everolimus, pazopanib, axitinib and tivozanib – have been approved for 
mRCC treatment (1,11,12).  Of these drugs, only bevacizumab is a mAb and it is targeted 
against VEGF.  The remaining 7 are SMIs that fall into two classes, receptor tyrosine 
kinase (RTK) inhibitors (RTKIs) and mammalian target of rapamycin (mTOR) inhibitors.   
The RTKIs that are approved and/or in clinical trials for ccRCC – sunitinib, sorafenib, 
pazopanib, axitinib and tivozanib – primarily act on endothelial cell VEGF and PDGF 
receptors, inhibiting signal transduction initiated by tumour cell-secreted VEGF and 
PDGF (1).  The mAb bevacizumab is specific for VEGF and prevents VEGF from 
interacting with its receptor on endothelial cells, thus inhibiting signaling between the 
tumour and blood vessels in a similar fashion (1).  In this way, RTKIs and bevacizumab 
target both current metastases – by preventing the initial attraction of blood vessels 
(neovascularization) to secondary tumours – and future metastases – by preventing the 
growth of new blood vessels towards the primary tumour (angiogenesis) that allow 
tumour cells to travel throughout the body (1).  While RTKIs can induce necrotic cell 
death in larger tumours as a result of decreased microvascular density (MVD), RTKIs 
display limited cytotoxicity when administered to ccRCC cells in vitro (43).  However, 
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some off-target effects of RTKIs acting on tumour cells directly have been documented.  
For example, some of sorafenib’s efficacy may stem from off-target inhibition of cyclin 
D1, cyclin B1 and survivin (44).  Likewise, sunitinib has been observed to enhance the 
anti-tumoural immune response by recruiting regulatory T-cells (45).  In general though, 
RTKIs and bevacizumab target mRCC by preventing vascularization of the primary 
tumour and its metastases, with the intention of enhancing cell death, reducing metabolic 
output, and preventing future metastases. 
Unlike RTKIs, mTOR inhibitors are more direct in their treatment of ccRCC in that they 
target a signaling pathway that is overactive in the cancer cells themselves.  mTOR can 
exist as a member of two functionally distinct complexes, mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2).  Both mTORC1 and mTORC2 regulate cell 
proliferation, cell survival, nutrient sensing, energy sensing, overall protein translation 
and angiogenesis, though their effects on these processes are not synonymous (1,46).  
The mTOR inhibitors currently approved for ccRCC – temsirolimus and everolimus – 
both prevent the formation of mTORC1, which results in decreased translation of HIF-
1α, cyclin D1 and c-MYC (1).  However as discussed previously, it is thought that HIF-
2α is responsible for most of the tumourigenic signaling in ccRCC, and its translation is 
primarily mediated by mTORC2 (47).  Furthermore, inhibition of mTORC1 alone has 
been shown to induce a paradoxical increase in the formation of mTORC2.  Therefore, 
while mTORC1 inhibitors may have some effect on cell proliferation and survival, they 
could actually be exacerbating the angiogenic response through increased activity of 
mTORC2, increased expression of HIF-2α and subsequent secretion of VEGF (48).  For 
this reason, SMIs that simultaneously target mTORC1/2 as well as the associated growth 
signaling kinases phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) are 
currently in development, though they have yet to reach clinical trials for management of 
mRCC (1,48). 
While RTKIs, mAbs that target VEGF, and mTOR inhibitors have all shown to improve 
PFS and objective response rates (ORR) when compared to cytokine-based therapies, 
many have noted that durable, complete responses remain rare.  Furthermore, while most 
assume that all of the approved targeted agents offer improved OS, improvements in OS 
9 
 
have only been objectively shown for some of the targeted agents, (1,11,12,31,34).  The 
adverse events associated with these targeted therapies, especially next generation RTKIs 
like pazopanib and tivozanib, are also considered to be less severe than those associated 
with cytokine-based therapies (12,42). For these reasons, RTKIs are now the current first-
line standard of care for patients with metastatic ccRCC and a favourable risk 
categorization (34).  However, given the relatively recent approval of these drugs for 
treatment of mRCC, there is a significant lack of prognostic information to aid clinicians 
in deciding which drugs are most likely to work in which patients, and the order in which 
they should be administered (12).  In fact, with the exception of bevacizumab + IFN-α, 
there is evidence to suggest that combined therapies – especially those combining 
multiple targeted therapies – are associated with serious adverse events (11).   
Significant investment has been made into developing and refining RTKI and mTOR 
inhibitors in order to increase their specificity, thus increasing potency and decreasing the 
likelihood of adverse events (12).  However, we already know that though RTKIs 
developed for ccRCC are anti-angiogenic, they are not cytotoxic in and of themselves 
(unless you consider their off-target effects).  Likewise, though mTOR inhibitors are 
cytotoxic, they are not anti-angiogenic (they may actually be pro-angiogenic).  Given the 
hazards associated with combined therapy, it seems that currently available treatment 
options are not capable of simultaneously targeting cell survival and angiogenesis, which 
may prove to be necessary in improving overall survival in a large proportion of patients 
(11).  In summary, while targeted therapies have shown to be effective, investigation into 
new targets that play a role in both survival and angiogenesis is something that should be 
considered. 
1.1.3 ccRCC Metabolism – The Warburg Effect 
VHL inactivation and HIF-α stabilization occur early in the development of ccRCC, 
however these events alone do not lead to ccRCC.  In fact 20% of VHL-knockout mice 
develop renal cysts that never progress to ccRCC (23).  Additional events such as 
activation of oncogenic signaling pathways, inactivation of DNA repair mechanisms, and 
changes in cellular metabolism are required before small renal masses can be considered 
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cancerous.  It is these additional events that further facilitate tumour progression, and 
might be better targets for therapy (14). 
The change in metabolism that occurs in ccRCC, and many other cancers, is known as 
the “Warburg Effect” and involves a shift from aerobic respiration pathways to anaerobic 
respiration pathways, even when oxygen is abundant (49-51).  Whereas aerobic 
respiration generates ATP through the tricarboxylic acid (TCA) cycle and the electron 
transport chain (ETC), anaerobic respiration generates ATP through glycolysis.  The 
switch to aerobic glycolysis occurs in almost all RCC histotypes as a result of HIF-1α 
accumulation.  While HIF-1α stabilization is due to VHL inactivation in ccRCC, its 
stabilization in other histotypes is due to mutation of key metabolic enzymes that 
ultimately result in inhibition of PHD (10,14).  Regardless of the mechanism, 
accumulation of HIF-1α subsequently results in the upregulation of key enzymes 
involved in glycolysis.  HIF-1α stabilization ultimately uncouples glycolysis from the 
TCA cycle via upregulation of pyruvate dehydrogenase kinase (PDK).  PDK inactivates 
pyruvate dehydrogenase (PD) through phosphorylation, thus preventing the end product 
of glycolysis, pyruvate, from heading towards aerobic metabolic pathways (14,51).  
Instead of heading towards the TCA cycle, pyruvate is converted into lactate via lactate 
dehydrogenase (LDH) – another HIF-1α  target – which allows for the regeneration of 
oxidized nicotinamide adenine dinucleotide (NAD
+
) from its reduced form (NADH) 
(14,52).  This alongside upregulation of GLUT-1 – yet another HIF-1α target – ensures 
that glycolysis substrates are in ample supply (14). 
From the perspective of ATP production, shifting metabolites away from oxidative 
phosphorylation – ATP produced by the ETC – and towards substrate-level 
phosphorylation – ATP produced by glycolysis – is energetically unfavourable when 
oxygen is available.  This has led cancer biologists to question the selective advantage 
that the Warburg Effect provides RCC and other cancers.  One selective advantage that 
has been suggested is the decreased production of reactive oxygen species (ROS) that 
comes with decreased oxidative phosphorylation (53).  In addition to uncoupling 
glycolysis from the TCA cycle by upregulating PDK, HIF-1α accumulation also leads to 
upregulation of the enzyme pyruvate kinase (PK) that facilitates the final step of 
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glycolysis – conversion of phosphoenolpyruvate into pyruvate.  PK comes in two 
isoforms, PKM1 and PKM2, which have variable activities.  ccRCC tumours often 
express the slower-acting PKM2 isoform as a result of c-MYC-mediated alternative 
splicing (54).  As a result of this delay at the end of glycolysis, metabolites produced 
earlier in the glycolytic pathway accumulate and are available for other processes.  One 
such process is the pentose phosphate pathway (PPP) which produces nicotinamide 
adenine dinucleotide phosphate (NADPH) – a molecule that helps cells cope with 
oxidative stress through various mechanisms – and molecules like ribose 5-phosphate and 
erythrose 4-phosphate – that are required for the synthesis of proteins and nucleic acids 
(53).  Therefore despite reducing overall ATP production, aerobic glycolysis ensures that 
the enhanced growth of RCC tumours occurs in a cellular environment in which; i) 
oxidative stress is regulated and ii) there are sufficient materials for production of 
biomass (53). 
HIF-1/2α accumulation also appears to suppress ROS production by inhibiting 
mitochondrial biogenesis, mitochondrial respiration and overall O2 consumption (55).  As 
mentioned earlier, ccRCC tumours often express elevated levels of c-MYC.  c-MYC can 
heterodimerize with MYC-associated factor X (MAX) to form a transcriptional activator 
of peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC-1β) – a 
gene that promotes mitochondrial biogenesis (55).  On the other hand, MAX can 
heterodimerize with MAX-interacting protein 1 (MXI1) to form a transcriptional 
repressor of PGC-1β, thus suppressing mitochondrial biogenesis.  MXI1 happens to be a 
target of HIF-1/2α and is overexpressed in ccRCC (56), which results in greater 
formation of MXI1:MAX than c-MYC:MAX, overall repression of mitochondrial 
biogenesis, and overall decreased O2 consumption (55).  There is also evidence that HIF-
1α-mediated upregulation of LDH inhibits mitochondrial respiration by competing for the 
same pool of NADH that is required for maintenance of the mitochondrial membrane 
potential and oxidative phosphorylation (52).  Not only is LDH more abundant, but its 
cytoplasmic localization and faster kinetics ensure that it is able to outcompete 
mitochondrial cytochrome oxidases for the NADH being produced by glycolysis (52).  
The end result is lower ETC activity, lower O2 consumption, and lower overall ROS 
production. 
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As the energetically preferred form of cellular metabolism, oxidative phosphorylation 
comes at the cost of increased ROS production.  When the earth’s atmosphere changed 
from a sulfide-rich environment to an oxygen-rich environment, bacterial and archaeal 
species were suddenly faced with a new molecule from which they were obligated to 
harness their energy.  Each species either slowly acquired this new metabolic phenotype 
via advantageous genetic mutations over many generations, or perished.  This concept, 
known as natural selection, is the driving force behind the evolution of species over time.  
However natural selection can apply to cells – malignant and benign – not just species as 
Darwin originally postulated (57).  Cells are able to sense changes in their environment 
and react in many ways, just like organisms.  Some of these mechanisms have been 
known for decades, some have only just come to light, and even more are still waiting to 
be discovered. 
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Figure 1.  VHL/HIF signalling under normoxic, hypoxic, and pseudohypoxic 
conditions in ccRCC. 
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1.2 Hydrogen Sulfide: The Third Gasotransmitter 
Gasotransmitters are small, gaseous, membrane-permeable molecules that are produced 
endogenously and in a dedicated fashion within mammalian cells in order to be perceived 
and invoke a response (58).  Two gaseous molecules – carbon monoxide (CO) and nitric 
oxide (NO) – are widely accepted to fit this definition and their effects within the body 
have been recognized since the 1960s and 1980s respectively (59,60).  The third and most 
recently discovered gasotransmitter is hydrogen sulfide (H2S), though its classification as 
a bona fide gasotransmitter is still up for debate (61).  While there is no doubt that H2S is 
a small, membrane-permeable molecule that is produced in a dedicated fashion in nearly 
all mammalian cells, there is some disagreement over whether changing levels of H2S can 
be sensed, or whether H2S itself is the sensor (61,62).  Regardless of how the semantics 
play out, it cannot be denied that H2S production in mammalian cells plays important 
roles in normal physiology and pathophysiology (58). 
It has long been known that at high enough concentrations H2S is a mitochondrial poison 
that inhibits Complex IV of the ETC and eliminates aerobic respiration (63).  As a result, 
nobody thought that H2S could possibly be playing a meaningful role in humans, despite 
the fact that there was knowledge of mammalian enzymes that produce H2S (64).  The 
first physiological function of H2S identified in mammals was its role as a 
neurotransmitter in the brain (65).  Soon after, H2S was shown to participate in 
synergistic smooth muscle relaxation alongside NO (66).  To this day, the functions of 
H2S are best described in the context of the central nervous system (67,68) and the 
cardiovascular system (69-71), although additional functions have been identified in the 
digestive system (72,73), musculo-skeletal system (74), endocrine system (75-77), 
excretory system (78-80), respiratory system (81,82) and reproductive system (83).  Not 
only does endogenous H2S production play a role in the normal functioning of these 
systems, but disruption of baseline H2S production has been implicated in diseases such 
as hypertension, Alzheimer’s Disease, diabetes mellitus, ulcerative colitis and end-stage 
renal disease (58,84,85).  Furthermore, the enzymes responsible for endogenous H2S 
production are expressed ubiquitously in human cells and H2S is found in the blood at 
nanomolar to micromolar concentrations (84). 
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1.2.1 H2S Production in the Kidneys: The Transsulfuration 
Pathway and Oxygen Sensing 
Scientists were able to measure endogenous H2S production in vivo before it was known 
to be physiologically relevant.  The first documented measurements of tissue-derived H2S 
were from rat liver and kidney and were simply used as a way to characterize the relative 
activities of the enzymes involved in the desulfhydration of L-cysteine (LC) (64).  The 
three enzymes that facilitate this process are cystathionine γ-lyase (CSE), cystathionine β-
synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (MPST).  At the time of these 
observations, it was known that the liver and kidneys were the major site for the 
desulfhydration of LC, although the ultimate purpose of this process was not entirely 
clear (64).  We now know that these enzymes are important in the kidney because in 
addition to facilitating the desulfhydration of LC, they also convert the toxic metabolite 
homocysteine (Hcy) into LC (86,87).  Together, the conversion of Hcy into LC, and 
subsequent processing of LC into sulfane sulfur (S
0
), sulfites (SO3
2-
), sulfates (SO4
2-
) and 
sulfides (S
2-
, HS
-
, H2S) is known as the transsulfuration pathway. 
It was previously thought that the production of H2S by CBS, CSE and MPST in the 
kidney was simply a byproduct of the transsulfuration pathway, necessary only for the 
purposes of chemical stoichiometry.  It has recently been shown that H2S derived from 
CSE and CBS is involved in regulating baseline hemodynamics and properties of renal 
tubules.  Notably, renal H2S concentrations were found to correlate with renal blood flow 
(RBF), glomerular filtration rate (GFR) and urinary excretion of Na
+
 and K
+
 – termed 
natriuresis and kaliuresis respectively (88).  While increased RBF and GFR are likely due 
to the well-known vasodilatory effects of H2S, increased natriuresis and kaliuresis are 
attributed to the inhibitory effect that H2S has on the Na
+
/K
+
 ATPase (NKA) and the 
Na
+
/K
+
/2Cl
−
 Co-transporter (NKCC) that maintain Na
+
 transport across renal epithelial 
cells (88).  There also appears to be a relationship between baseline H2S production, 
production of ROS, and regulation of systemic blood pressure through the renin-
angiotensin system (RAS) that is regulated by mesangial cells (89,90).  Although CBS 
and CSE are noticeably lacking from glomerular epithelial cells, H2S produced in nearby 
proximal tubule epithelial cells may act on glomerular epithelial cells in a paracrine 
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fashion to influence global protein synthesis through AMP-activated protein kinase and 
mTORC1 (91-93).  Similar paracrine functioning of H2S has been implicated in the 
vasodilation of proximal tubule capillaries, which also lack CBS and CSE (91). 
One postulated function of H2S within the kidney is oxygen sensing (94).  This recently 
proposed hypothesis builds on empirical evidence that demonstrates that the relative 
proportion of sulfur in its oxidized forms (SOx) and reduced forms (HxS) depends on O2 
availability (81).  When O2 is available under normoxia, the oxidized forms of sulfur are 
favoured.  Conversely, when O2 is scarce under hypoxia, the reduced forms of sulfur, 
such as H2S, are favoured.  This is no doubt an oversimplified model, nonetheless there is 
significant evidence demonstrating that oxidation of H2S is an effective cellular 
mechanism of sensing decreases in O2 in a wide variety of tissues (62,95).  Beltowski 
proposes that this acute mechanism may be important in regulating oxygenation to the 
renal medulla – an area of the kidney that requires tight regulation of blood flow in order 
to achieve the balance between hyperosmolality and O2 supply that is required for the 
concentration of urine.  Maintenance of this steep concentration gradient in the medulla 
requires high expression of NKCC channels and comes at the cost of significant O2 
consumption (60% of total renal O2 consumption) (94).  To ensure that maintenance of 
the gradient does not starve medullary cells of O2, it is thought that high CBS expression 
in these cells results in accumulation of H2S under hypoxia, inhibition of NKCC and 
NKA to reduce O2 demand, and vasodilation of descending vasa recta to increase O2 
supply (93,94). 
There is much that remains to be investigated regarding the role that endogenous H2S 
production plays in maintaining normal renal function, however it is clear that its 
presence cannot simply be described as a byproduct of transsulfuration.  
1.2.2 H2S Production, Reactivity and Signalling  
Gasotransmitters are by no means traditional signalling molecules.  Unlike hormones and 
neurotransmitters, gasotransmitters are not suitable for long- or even short-term storage.  
There are no dedicated receptors for gasotransmitters, nor is there a need for channels to 
facilitate the movement of gasotransmitters across cell membranes due to their 
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hydrophobicity.  As such, once gasotransmitters are enzymatically produced, they are 
immediately able to react with various functional groups in their nearby surroundings.  
Given the lack of control that the cell has on these molecules following their synthesis, it 
is imperative that their production is tightly regulated at the level of enzyme expression 
and activity (96). 
H2S is synthesized by three enzymes, two of which are localized primarily to the 
cytoplasm (CBS and CSE), the other of which is localized primarily to the mitochondria 
(MPST), although CBS and CSE have been observed in the nucleus and MPST in the 
cytoplasm (97).  CBS is primarily regulated post-translationally through various 
mechanisms, although its transcription has been shown to be regulated by numerous 
transcription factors, including HIF-1/2α (98,99).  CBS contains a redox-sensitive heme 
co-factor which can regulate enzyme activity in response to other gasotransmitters as well 
as oxidative stress.  While oxidative stress activates CBS, presence of NO and/or CO 
inhibits CBS (100).  CBS can also be allosterically activated by S-adenosylmethionine, 
which is a precursor of CBS’s major substrate homocysteine (96).  Regulation of MPST 
is also primarily achieved through post-translational mechanisms.  Various intra- and 
inter-molecular disulfide bridges can form between cysteine residues under oxidative 
conditions, inactivating the enzyme.  The presence of certain reducing substrates may 
regulate MPST activity by helping to break these inhibitory disulfide bonds under 
conditions of oxidative stress (101).  Conversely, little is known regarding post-
translational control of CSE activity, although its transcription may be inhibited by n-
MYC (98).   
Once produced, H2S exists in an equilibrium with its anionic form (HS
-
) and is also 
capable of forming reactive polymerized structures known as polysulfides, the effects of 
which may be restricted to the cells in which they are produced (67,96).  While some 
believe that the effects of H2S may actually be mediated by these other reactive sulfur 
species, it is generally accepted that H2S exerts its effects by modifying protein activity 
post-translationally by reacting with thiol groups of cysteine residues (102).  This 
reaction – known as S-sulfhydration – results in the formation of a sulfhydryl group (R-S-
S-H) that alters protein structure and function.  From a chemistry standpoint, S-
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sulfhydration is very similar to the reaction by which NO interacts with cysteine residues 
– known as S-nitrosylation – however the biological effects of these two gasotransmitter-
mediated post-translational modifications are very different (96,103).  Whereas S-
nitrosylation often results in the inhibition of target proteins, S-sulfhydration can be both 
inhibitory and stimulatory.  Often, a protein’s activity depends on whether key cysteine 
residues have been S-nitrosylated (inactive) or S-sulfhydrated (active) (96).  This can be 
said for glyceraldehyde 3-phosphatase (GAPDH), a key regulator of glycolysis.  S-
Sulfhydration of GAPDH at Cys150 results in a 700% increase in its glycolytic activity 
whereas S-nitrosylation of this same residue inhibits the enzyme’s glycolytic function 
(102).  Competition between H2S, NO and ROS for cysteine residues is likely a way by 
which cells buffer the effects of any one of these gaseous molecules, ensuring that a 
response is triggered only when levels of one of these molecules significantly outweighs 
the others (61). 
In addition to altering the activity of phosphatases like GAPDH, H2S also affects the 
activity of kinases, ion channels and transcription factors that are involved in regulating 
cell survival, cell proliferation, membrane polarization, angiogenesis and inflammation 
(104).  S-sulfhydration of ATP-dependent K
+
 (KATP) channels is a stimulant of 
vasodilation in the cardiovascular system that may be more potent than NO-mediated 
vasodilation (105).  H2S has also been shown to promote the anti-apoptotic signaling 
cascade initiated by tumour necrosis factor alpha (TNF-α) through S-sulfhydration of the 
p65 subunit of the transcription factor nuclear factor kappa B (NF-κB) (106).  Finally, 
H2S can activate various kinases that promote proliferation and angiogenesis – such as 
Akt, protein kinase C (PKC), mitogen-activated protein kinase p38 (p38) and 
extracellular signal-related protein kinase (ERK 1/2) – although S-sulfhydration of 
kinases is rarely documented in the literature (104). 
1.2.3 H2S: Vasodilator and Angiogenic Factor 
The synergistic effects of H2S and NO in the cardiovascular system have been known for 
quite some time (66).  As previously mentioned, both of these gasotransmitters are potent 
vasodilators, and their effects may be mutually dependent on one another.  Recent work 
has demonstrated that H2S and NO are also mutually-dependent stimulants of 
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angiogenesis (107).  Both vasodilation and angiogenesis are important physiological 
responses that occur in response to disruption of normal blood supply following various 
ischemic injuries.  Whereas vasodilation involves increasing blood flow via relaxation of 
smooth muscle cells that surround blood vessels, angiogenesis increases blood flow via 
the growth and recruitment of new vascular networks, which requires the proliferation 
and migration of endothelial cells.  At first glance these responses appear to be quite 
distinct, however closer inspection reveals that H2S and NO coordinate these responses 
using the same pathway (107). 
Activation of protein kinase G (PKG) is the junction at which gasotransmitter production 
and the induction of angiogenesis/vasodilation meet.  In order for PKG to phosphorylate 
its target proteins, the co-factor cyclic guanosine monophosphate (cGMP) is required.  
Production of cGMP is accomplished via guanylyl cyclase (GC), and degradation of 
cGMP is accomplished via phosphodiesterase type 5 (PDE5).  cGMP levels rise in the 
presence of NO and H2S because NO activates GC – increasing cGMP production – and 
H2S tonically inhibits PDE5 – decreasing cGMP degradation (107).  Knock-out/inhibition 
of either one of the major endothelial enzymes responsible for NO and H2S synthesis – 
endothelial nitric oxide synthase (eNOS) and CSE respectively – results in complete loss 
of the angiogenic response to VEGF and the vasodilatory response to cholinergic 
stimulation (107,108).  This suggests that baseline production of H2S and NO in 
endothelial cells is a necessary component of these cardiovascular responses.  
Focusing on the angiogenic response, several groups have shown that exogenous H2S can 
induce endothelial cell proliferation, tube formation and migration via PKG-mediated 
phosphorylation of ERK 1/2 and p38 (107-109).  What is more interesting, is that VEGF-
mediated angiogenesis appears to require endogenous H2S production, suggesting that 
VEGF exerts its angiogenic effects through H2S (108).  In addition to inhibiting cGMP 
degradation by PDE5, it is thought that increasing levels of H2S may increase cGMP via 
Akt-mediated activation of eNOS (107).  This is based on evidence that Akt is activated 
in response to exogenous/endogenous H2S production, albeit the mechanism is not 
currently known (107-109).  The exact mechanisms that link VEGF, H2S and NO are still 
being worked out, however a relationship surely exists. 
20 
 
1.2.4 H2S: Antioxidative and Cytoprotective 
When referring to oxidative damage, one is referring to the damage that cells incur as a 
result of generating ATP through oxidative phosphorylation.  As the ultimate acceptor of 
electrons utilized in the ETC, O2 must be present in abundance to ensure that electrons 
are quenched in pairs and not in isolation.  When molecules with stable electronic 
configuration happen to accept a single electron, the result is an unstable free radical that 
can disrupt cellular function by inappropriately reacting with and damaging DNA, 
proteins and lipids.  Free radicals that are most commonly formed in cells usually contain 
oxygen – referred to as ROS – or nitrogen – referred to as reactive nitrogen species 
(RNS).  While the presence of moderate levels of ROS/RNS is normal and even 
necessary for appropriate cell signaling, excessive production of ROS/RNS has been 
implicated in several diseases, many of them age-associated.  While mitochondrial 
dysfunction and other kinds of cell stress result in oxidative damage as a result of 
increased ROS/RNS production, oxidative damage can also occur as a result of decreased 
degradation of ROS/RNS by antioxidative mechanisms (110). 
Several studies have shown that exogenous administration and/or endogenous production 
of H2S can attenuate injury and cellular senescence caused by oxidative stress (111-115).  
It was originally believed that H2S mediates these antioxidative effects by reacting 
directly with ROS and RNS.  However, due to the relatively low abundance of H2S 
compared to other cellular reductants like glutathione, as well as the low rate constants 
for H2S-mediated oxidation, it seems likely that this is not the case (111).  To explain the 
antioxidative properties of H2S, it has been postulated that they could simply be the result 
of reversible Complex IV inhibition, decreasing metabolic rate and overall ROS 
production (116).  H2S has also been shown to react with electrophiles that are generated 
during oxidative damage and lead cells down cell death/senescence pathways.  In this 
way H2S blunts the cell’s response to oxidative stress, promoting damage recovery as 
opposed to cell death (117).  Along the same line, H2S can abrogate apoptosis by 
counteracting declines in mitochondrial membrane potential and preventing caspase 
activation (112). 
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Alternatively, exogenous H2S can induce the antioxidant response through regulation of 
the master transcription factor NF-E2 p45-related factor 2 (Nrf2).  Under normal REDOX 
conditions, Nrf2 is degraded by kelch-like ECH-associated protein-associated protein-1 
(Keap1), however under oxidative stress H2S inactivates Keap1 through S-sulfhydration, 
allowing Nrf2 to accumulate and induce expression of antioxidative proteins (118).  
Interestingly, CBS and CSE are amongst the antioxidative proteins that are induced by 
Nrf-2, creating a positive feedback loop in which H2S production plays a central role 
(118).  This positive feedback loop could explain how H2S can pre-condition cells to 
various forms of injury that involve oxidative stress (119).  Regardless of the mechanism, 
H2S is clearly playing an important role in responding to oxidative stress. 
1.2.5 H2S: Metabolic Substrate and Regulator 
Given its toxic reputation, it is rather hard to believe that H2S could be contributing to 
mammalian cellular metabolism in any meaningful way.  The existence of prokaryotes 
that oxidize sulfides for energy production has been known for decades.  However, these 
anaerobic organisms – which usually inhabit sulfide-rich environments like the deep 
ocean or volcanic springs similar to primordial earth– cannot rely on oxidative 
phosphorylation for ATP production like humans and other aerobic organisms do.  
However, when one considers the endosymbiotic relationship that links eukaryotic 
mitochondria with ancient sulfide-oxidizing prokaryotes, perhaps it is not surprising that 
eukaryotes retained a sulfide oxidation pathway (120).  Conversion of H2S into persulfide 
(S2
2-
), sulfite (SO3
2-
), thiosulfate (S2O3
2-
) and sulfate (SO4
2-
) occurs under aerobic 
conditions and is important in ensuring that H2S does not inhibit the heme co-factors of 
Complex IV of the ETC, halting oxidative phosphorylation and ATP synthesis (121).  In 
fact, given the high flux of sulfur into H2S we know that most of the H2S being produced 
under normoxic conditions is removed via mitochondrial oxidation in order to account for 
the relatively low concentration of H2S in mammalian tissues (111).  This is especially 
true for epithelial cells of the kidney and colon which are exposed to high levels of H2S 
produced by the transsulfuration pathway and H2S-producing bacteria respectively (122).  
While these physiological adaptations are impressive in their own right, what is truly 
impressive is that these, and other cells of the body, are capable of funneling the electrons 
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liberated by sulfide oxidation into the ETC to contribute to ATP production.  This makes 
H2S the first inorganic substrate for oxidative phosphorylation identified in mammalian 
cells (121). 
The first step of sulfide oxidation in mammalian cells is the transfer of electrons from 
H2S to coenzyme quinone (Q), which is catalyzed by sulfide quinone reductase (SQR) 
(122).  When compared to the canonical players involved in the ETC, H2S is analogous to 
NADH in that they are both the primary donors of electrons, and SQR is analogous to 
Complex I in that they both feed into coenzyme Q (120).  Following loss of its electrons, 
H2S is processed by a sulfide-oxidizing unit (SOU) consisting of a dioxygenase and 
sulfurtransferase through a mechanism that requires one molecule of O2.  In this way, 
oxidation of 1 mole of H2S requires 1.5 moles of O2 (1 mole for SOU and 0.5 moles for 
Complex IV), which is considerably more than the 0.5 moles of O2 required for oxidation 
of NADH.  Therefore, oxidation of sulfide in eukaryotes is an oxygen-dependent process, 
which is why H2S levels rise under hypoxia (62).  The differences in stoichiometry also 
highlight that oxidation of H2S is energetically less favourable than oxidation of NADH 
in that it only supplies half of the electrons.  Furthermore, catabolism of L-cysteine into 
pyruvate would yield ten times the number of electrons available for oxidative 
phosphorylation when compared to catabolism of L-cysteine into H2S.  This prompts the 
question “Why would eukaryotic cells saturate the activity of coenzyme Q with H2S/SQR 
when electron transport through NADH/Complex I is much more efficient?” (120). 
The reasons for this are three-fold, and together they emphasize the role of H2S as an 
‘emergency substrate.’  First and foremost, H2S is membrane-permeable so gaining 
access to the mitochondria does not require additional energy expenditure for transport 
and also occurs rapidly.  Second, production of H2S from L-cysteine does not require 
energy investment as is the case for metabolism of carbon sources which requires initial 
activation before reducing agents like NADH can be produced.  Finally, the SOU has a 
high affinity for H2S when present at physiological concentrations which ensures that 
nearly all of it is used for production of ATP (120).  The role of H2S as an emergency 
metabolic substrate following various stresses has been demonstrated in smooth muscle 
cells and hepatocytes (123,124). 
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Tackling this issue from another angle, it has also been suggested that by competing with 
electron donors from carbon-based metabolism, H2S may play a role in fine-tuning 
oxygen consumption.  It has been shown that moderate levels of H2S (100 nM – 10 μM) 
can stimulate oxygen consumption in the presence of various carbon-based metabolic 
substrates in vitro, whereas higher levels of H2S (>10 μM) overwhelm the SOU, inhibit 
Complex IV and decrease oxygen consumption (125).  Increasing oxygen consumption 
through the SOU can be useful in reducing oxidative stress associated with oxidative 
phosphorylation and may be a key link between cellular REDOX potential and cellular 
metabolism.  With increased aerobic respiration comes increased risk of oxidative stress, 
however moderate H2S production may allow cells to achieve the same metabolic output 
with less oxidative damage.  Production of H2S also increases glycolysis through S-
sulfhydration of GAPDH, as previously mentioned. 
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Figure 2. Cellular H2S metabolism and signalling. 
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1.3 H2S and Cancer 
Given its many properties, the therapeutic potential of H2S has been investigated in many 
disease states, including cancer.  In many of these disease states endogenous H2S 
production seems to have been suppressed or lost, in which case exogenous 
administration of H2S has been investigated as a treatment option.  In these cases, 
determining the proper dose, method of administration, and even rate of release through 
the use of slow-release H2S-donour molecules are major challenges due to the small 
range of concentrations at which H2S is effective before it becomes toxic (85).  These 
same issues have led to conflicting results on the role that H2S plays in various cancers. 
1.3.1 Exogenous H2S as a Cancer Treatment? 
It has been shown that exogenous H2S treatment can restrict gastric cancer growth and 
survival, although the dose used in vitro was not shown to be non-toxic to non-malignant 
cells and the mechanism of action in vivo was not identified (126).  Exogenous H2S 
treatment has also been shown to target the growth and survival of oral cancer, breast 
cancer and hepatoma cell lines over non-malignant cell lines of similar origin.  However 
the pro-apoptotic effects of H2S in these instances are reliant on the presence/absence of 
certain proteins (127,128).  If one believes that proliferating cancer cells are affected by 
natural selection in the same way that all organisms are, then one would expect that 
endogenous H2S production would be down-regulated if H2S is indeed anti-tumoural.  
However, decreased expression of H2S-producing enzymes – and decreased endogenous 
H2S production – has only been shown in aggressive prostate cancer cell lines (129).  In 
fact, the opposite seems to be true when evaluating endogenous H2S production in most 
cancer cell lines, and inhibition of this enhanced H2S production targets cell growth, 
survival, metabolic output, migration, angiogenic potential and therapy-resistance. 
1.3.2 Role of Endogenous H2S Production in Cancer 
Much attention has been paid to the role that endogenous H2S production plays in the 
progression of colon cancer, given that the colon is rich in bacterial H2S that is 
continuously being oxidized in the mitochondria of colonocytes (122).  It was first shown 
that exogenous H2S treatment could enhance cell cycle entry in several colon cancer cell 
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lines by increasing Akt activation and decreasing expression of the cell cycle inhibitor 
p21 (130).  More recently, it was shown that several malignant traits of colon cancer were 
due to enhanced expression of CBS in human tumours and malignant cell lines when 
compared to non-malignant samples (131).  In addition to facilitating proliferation in 
vitro, increased endogenous H2S production was contributing to cell migration and cell 
bioenergetics.  When cell lines were xenografted in vivo, silencing/inhibition of CBS 
could attenuate tumour growth and blood supply (131).  CSE has also been implicated in 
facilitating colon cancer growth, migration and vascularization, and its expression 
appears to be transcriptionally up-regulated in cell lines characterized by aberrant Wnt 
signalling (132). 
CBS was also found to be upregulated in human epithelial ovarian cancer cell lines and 
tissue samples when compared to normal epithelial cells, and inhibition/knock-down of 
CBS restricted cell growth, cell viability and cellular metabolism in vitro.  When 
xenoplanted into mice, silencing of CBS was also able to reduce xenograft 
neovascularization and sensitized tumours to platinum-based chemotherapy which cells 
had previously been resistant towards (133).  Whether H2S itself was able to protect 
against the oxidative stress induced by the chemotherapy was not investigated, however it 
has been shown that induction of CBS/CSE and elevated H2S production under hypoxia 
contributes to hypoxia-induced radiation therapy resistance in hepatoma cells (134).  It 
has also been suggested that bystander effects – tumour cell death surrounding the 
irradiated area of the tumour – in hepatocellular carcinoma may also be the result of 
decreased endogenous H2S synthesis (135).  Together, these studies suggest that 
inhibition of endogenous H2S production could prove to be an effective adjuvant therapy 
in tumours such as ccRCC that are hypoxic and/or resistant to chemotherapy/radiation 
therapy. 
An important aspect of natural selection is the presence of a selective pressure.  From the 
point of view of cancer cells, naturally occurring selective pressures include hypoxia, 
nutrient deprivation, and oxidative stress.  However, by targeting cancer cells with 
specific therapies we can introduce additional selective pressures that cancer cells may or 
may not adapt to.  Only a subset of cells will survive these pressures, proliferate and lead 
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to changes in the cellular make-up and behaviour of tumours over time, a process referred 
to as tumour progression (136).  Recent studies have shown that breast, liver and colon 
cancer cell lines are able to recover from cell damage induced by nutrient deprivation, 
hypoxia, oxidative stress and chemotherapeutics through a mechanism involving H2S 
(137,138).  Essentially, damage-recovered cells exhibit increased endogenous H2S 
production which upregulates nicotinamide phosphoribosyltransferase (Nampt), an 
enzyme involved in salvaging NAD
+
 and driving aerobic glycolysis.  Damage-recovered 
cells therefore display reduced mitochondrial bioenergetics, increased aerobic glycolysis, 
increased resistance to oxidative stress, and increased proliferation as a result of this H2S-
Nampt pathway (138).  This same pathway has also been shown to be associated with the 
stem-like phenotype of cancer cells that survive such damage (139). 
1.3.3 Role of H2S in kidney cancer 
Renal malignancies, specifically ccRCC tumours, have been described as metabolic 
diseases that display dysfunctional oxygen-, nutrient-, and energy-sensing pathways (9).  
Functional loss of the tumour suppressor VHL is responsible for this dysfunction in that it 
results in the accumulation of HIF-1/2α, rendering ccRCC tumours pseudohypoxic (14).  
This pseudohypoxia results in an overall shift in metabolism that results in the activation 
of aerobic glycolysis, suppression of mitochondrial bioenergetics, and flux of glycolytic 
metabolites towards production of reducing agents and biomass – otherwise known as the 
Warburg Effect (53).  Finally, pseudohypoxic ccRCC tumours are highly angiogenic due 
to their high secretion of VEGF, which increases their access to vasculature and the rest 
of the body (18). 
H2S is an endogenously-produced molecule that functions as an oxygen sensor (62), 
angiogenic factor (108), metabolic substrate (122), and cytoprotectant (111).  In renal 
epithelial cells, H2S is produced in abundance by enzymes that are involved in the 
detoxification of homocysteine (64) and this excessive H2S is readily oxidized by 
mitochondria under normoxia, contributing to ATP production (122).  In the context of 
other cancers, it is known that elevated levels of H2S can enhance ATP production and 
reduce oxidative stress via mitochondrial oxidation (131,133) or enhanced aerobic 
glycolysis (137,138).  Finally, endogenous H2S production appears to confer resistance to 
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natural pressures felt by cancer cells as well as clinically-administered pressures like 
chemotherapy and radiation therapy (134,139). 
Taken together, there is considerable evidence to suggest that endogenous H2S 
production plays an important role in the progression of kidney cancer, and inhibiting its 
production may be a legitimate course of treatment.  Specifically, pseudohypoxic ccRCC 
tumours may produce particularly high levels of H2S as a result of decreased removal of 
H2S via oxidation and increased expression of CBS via HIF-1/2α (99). 
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1.4 Hypothesis and Objectives 
1.4.1 Hypothesis 
It is hypothesized that endogenous production of H2S is upregulated in VHL-deficient 
ccRCC cell lines and tumours, and contributes to their survival, growth and angiogenic 
potential. 
1.4.2 Objective I: Is Endogenous H2S Production Enhanced in 
VHL-deficient ccRCC Cell Lines? 
Our first objective was to determine whether endogenous production of H2S is enhanced 
in VHL-deficient ccRCC cell lines.  To investigate this, five cell lines were used.  The 
non-malignant, human, renal epithelial cell line HK-2 served as the control for four 
different ccRCC cell lines: the VHL WT ccRCC cell line Caki-1, two VHL-deficient 
ccRCC cell lines 769-P and 786-O, and a 786-O cell line with VHL function restored 
using an exogenous lentiviral vector containing a single wild-type allele of the gene (786-
O VHL+). 
As a result of its gaseous nature, quantification of cellular H2S production has proven 
difficult and has been a significant hurdle in this field of research.  Recently published 
articles documenting endogenous H2S production often use the Methylene Blue Assay 
which has been practiced since the 1970s but is known to produce false-positive results 
by reacting non-specifically with thiols.  To avoid such false positive results, we used a 
cell-permeable, H2S-specific, fluorescent probe in combination with live-cell imaging to 
track endogenous H2S production in our cell cultures in real-time.  Cells in the 
presence/absence of the probe were imaged at the beginning of experiments as a control 
to demonstrate that differences in fluorescent signal were the result of differences in H2S 
production, and not differences in background fluorescence.  Use of this probe was 
impractical in the 786-O VHL+ cell line due to high background fluorescence, and so the 
Methylene Blue Assay was used instead in its stead, with heat-killed cells serving as a 
control against false-positive results. 
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Since the probe only quantifies net H2S production, it alone cannot distinguish between 
cell cultures that have a high concentration of H2S due to enhanced production, and cell 
cultures that have a high concentration of H2S due to dysfunctional clearance.  To more 
adequately address whether VHL-deficient ccRCC cell lines display enhanced production 
of H2S, western blot analysis of baseline CBS, CSE and MPST expression was 
performed.  Hypoxic induction of CBS/CSE/MPST expression was also investigated 
using western blot analysis to try and establish links between expression of H2S-
producing enzymes, VHL functional status, and HIF-1/2α expression. 
1.4.3 Objective II: Does Endogenous H2S Production Contribute to 
the Proliferation, Metabolism and Survival of ccRCC Cell 
Lines? 
Our second objective was to determine whether endogenous production of H2S 
contributes to the proliferation, metabolism and survival of ccRCC cell lines.  In order to 
determine whether endogenous H2S production can be inhibited in our cell lines we 
treated them with the validated CBS/CSE inhibitors hydroxylamine (HA) and propargyl 
glycine (PAG) (140) and monitored changes in H2S production using the fluorescent 
probe described in Objective I.  Treating cells with the substrate for endogenous H2S 
production (LC) allowed us to evaluate whether endogenous H2S production can be 
stimulated above baseline levels, or whether it is at capacity.  Combination treatment of 
cells with HA and LC will allow us to determine if we can partially rescue H2S 
production with LC when the inhibitor is present.  Cells were left untreated as a control, 
seeing as HA, PAG and LC were all dissolved in phosphate-buffered saline (PBS). 
Using these treatments under both normoxic (21% O2) and hypoxic (1% O2) growth 
conditions, we evaluated how changing endogenous production of H2S influenced cell 
growth, cell survival, and cell metabolism in vitro.  Changes in cell growth were 
quantified by measuring changes in confluency over time.  Cell viability was quantified 
via flow cytometry identification of the apoptotic and necrotic markers Annexin-V and 7-
AAD, respectively.  Finally, cell metabolism was quantified using a combination of the 
XTT Assay – which quantitates electron turnover by spectrophotometric changes – and 
an ATP quantitation kit – which measures cellular ATP concentration using a luciferin-
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luciferase system.  The role that VHL mutation status plays in conferring 
resistance/susceptibility to such treatments was further investigated here. 
1.4.4 Objective III: Does Endogenous H2S Production Contribute 
to Neovascularization of ccRCC Xenografts? 
Our third objective was to determine whether endogenous production of H2S contributes 
to the neovascularization of ccRCC xenografts.  In order to investigate this, ccRCC cell 
lines were xenografted into the chorioallantoic membranes (CAMs) of developing 
chicken embryos.  This immune-deficient xenograft model is ideal for studying the 
neovascularization of human tumours in real-time (141), and has also been used to study 
the effects of H2S on angiogenesis (108).  Treatments were administered systemically to 
determine whether changes in endogenous H2S production can influence the recruitment 
of blood vessels to ccRCC tumours.  PBS was injected intravascularly as a control.  The 
effect of treatments on tumour size was also investigated, as well as the efficacy of 
treatments in relation to VHL mutation status.  
1.4.5 Objective IV: Is Endogenous H2S Production Enhanced in 
human RCC tumours? 
Our fourth and final objective was to determine whether expression of the H2S-producing 
enzymes CBS and CSE is upregulated in human RCC tumours.  In order to investigate 
this, immunohistochemical staining of CBS and CSE was performed on samples derived 
from 49 patients with renal masses.  Tissue was also harvested from non-neoplastic areas 
of the affected kidney to serve as an internal control.  Expression of each protein in 
ccRCC tissue was pathologically scored and compared to expression in normal renal 
tissue from the same patient, as well as expression in non-malignant and non-ccRCC 
renal masses.  Correlations to Fuhrman grade – a pathological indicator of disease 
severity – and tumour size were also performed.  
 
32 
 
2. Materials and Methods 
2.1 Cell Culture 
All cells were cultured under normal growth conditions (37 °C, 5% CO2, 21% O2) in 
growth media (Gibco®, Burlington, ON) supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin. Subculturing of cells was performed weekly with use of 
0.05% trypsin EDTA (Gibco®).  The human renal epithelial cell line HK-2 was 
generously donated by Dr. Lakshman Gunaratnam (Western University, London, ON) 
and cultured in Keratinocyte Serum Free Medium supplemented with human recombinant 
Epidermal Growth Factor 1-53 and Bovine Pituitary Extract.  The VHL WT ccRCC cell 
line Caki-1 was generously donated by Dr. Alison Allan (Western University, London, 
ON) and cultured in McCoy’s 5A growth medium.  The VHL-deficient ccRCC cell lines 
769-P and 786-O were also donated by Dr. L. Gunaratnam and cultured in Dulbecco’s 
Modified Eagle Medium.  The ccRCC 786-O VHL+ cell line was generously donated by 
Dr. James Brugarolas (UT Southwestern, Dallas, TX) and grown in Dulbecco’s Modified 
Eagle Medium. 
2.2 Treatments 
Inhibitors of endogenous H2S synthesis (HA and PAG) and the substrate for endogenous 
H2S production (LC), were prepared as 100 mM stock solutions in PBS.  Effective doses 
ranged from 0.5 mM to 5 mM, depending on the assay, and were used to treat cells 
seeded in 96-well, 24-well, 12-well or 6-well plates.  Cells were treated for 6-48 hours in 
either normoxic growth conditions (37 °C, 5% CO2, 21% O2) or hypoxic growth 
conditions (37 °C, 5% CO2, 1% O2) using a HypOxystation® H85 hypoxia chamber 
(HYPO2XYGEN, Frederick, MD). 
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2.3 Measurement of Endogenous H2S Production 
2.3.1 Live Cell Imaging with Fluorescent Probe 
A cell-permeable, H2S-specific, fluorescent probe was used in combination with live-cell 
imaging to track endogenous H2S production in our cell cultures in real-time.  The H2S-
specific probe was generously donated by Dr. Michael Pluth (University of Oregon, 
Eugene, OR) and is the second-generation product of probes previously developed in the 
Pluth lab.  The probe is an azide-functionalized fluorophore that reacts specifically with 
H2S to produce a green fluorescent signal (142).  The live-cell imaging platform used 
here was the IncuCyte ZOOM (Essen BioScience, Ann Arbour, MI) and its use was 
graciously afforded by Dr. Anthony Jevnikar (Western University, London, ON).  Cells 
were seeded into 96-well plates (2 x 10
4
 cells per well) and allowed to adhere overnight.  
Treatments and H2S-specific probe were added to wells simultaneously and green 
channel fluorescent images of each well were captured every 30 minutes for 15 hours (4X 
objective, 440 nm excitation/520 nm emission).  Using IncuCyte internal software, 
thresholding was performed on wells in which no H2S-specific probe had been added in 
order to eliminate background cellular fluorescence.  The total number of cells 
fluorescing above the established threshold was quantified, yielding a Total Probe Count.  
IncuCyte internal software was also able to quantify percentage cell confluency after 
additional thresholding, and this was used to normalize the Total Probe Count. 
2.3.2 Methylene Blue Assay 
Cells were seeded into 6-well plates and allowed to reach 90% confluency.  Growth 
media was aspirated and cells were washed twice with PBS before the addition of 50 μL 
of lysis buffer.  Immediately, a solution of zinc acetate (12% NaOH) was added to each 
sample to ‘capture’ H2S released by lysis.  Subsequent reaction with 20 mM N,N-
dimethyl-p-phenylenediamine in 7.2 M HCl and 30 mM FeCl3 in 1.2 M HCl allowed for 
a colour change to occur over 10 minutes which was spectrophotometrically quantified at 
670 nm.  Standard H2S solutions were prepared by dissolving Na2S in lysis buffer and 
were processed in parallel.  Heat-killed cell pellets were also processed in parallel to 
serve as a negative control. 
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2.4 Protein Expression Analysis 
2.4.1 Protein Isolation 
Cells were plated into 60 mm dishes and allowed to reach 90-100% confluency.  Cells 
were either kept in normoxia or exposed to hypoxia for 6-24 hours.  Following treatment, 
media was aspirated, cells were washed twice with PBS before being lysed on ice for 15 
minutes in RIPA buffer.  Lysates were collected and centrifuged at 4 °C and 10,000 x g 
for 10 minutes before being aliquoted and stored at -80 °C.   
2.4.2 SDS-PAGE and Western Blotting 
Forty-fifty micrograms of each sample was run on 10-12%, Tris-glycine, SDS-
polyacrylamide gels under thiol-reducing conditions at 60-120 V and transferred to 
PVDF membranes for 45 minutes at 80V.  Membranes were blocked in TBS (5% BSA) 
and incubated overnight at 4°C with primary antibody (mouse-anti-human CBS (B-4): 
Santa Cruz Biotechnology Inc., sc-133154; rabbit-anti-human CTH (CSE): Sigma 
Aldrich, SAB2100501; mouse-anti-human MPST (D-8): Santa Cruz Biotechnology Inc., 
sc-374326; mouse-anti-human β-actin: Sigma Aldrich, A5441).  Membranes were 
washed in TBS (1% Tween-20) for 3 x 10 minutes, incubated with HRP-conjugated 
secondary antibody (goat-anti-mouse IgG HRP conjugate: Life Technologies™, G-
21040; goat-anti-rabbit IgG-HRP-conjugate: Jackson Immunoresearch Laboratories Inc., 
111-035-003) for 1 hour at room temperature and washed for 3 x 10 minutes.  
Chemiluminescence was induced using Luminata™ Crescendo Western HRP Substrate 
(EMD Millipore, WBLUR0100A).   
2.4.3 Imaging and Analysis 
The majority of blots were imaged using the C-DiGit® Blot Scanner (LI-COR) and 
subsequently analyzed using Image Studio Lite version 4.0.  Due to equipment 
malfunction, some blots were imaged using the FluorChem™ M System (ProteinSimple, 
Toronto, ON) and band density was determined using a combination of internal software 
(for most blots) and ImageJ Software (for blots with low signal). 
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2.5 Cell Proliferation Assay 
Cells were seeded into 96-well plates (1 x 10
4
 cells per well) and allowed to adhere 
overnight, resulting in roughly 50% confluency at the time of treatment.  Treatments 
were added to wells and images (4X magnification) of each well were captured every 30 
minutes for 12 hours using the IncuCyte ZOOM live-cell imaging platform (Essen 
BioScience, Ann Arbour, MI).  Using IncuCyte internal software, thresholding was 
performed on wells in which cells received no treatment in order to optimize the 
quantitation of cell confluency.  The percentage change in confluency for each individual 
well was then calculated. 
2.6 Cell Viability Assay 
Cells were seeded into 12-well plates and allowed to reach 70-90% confluency.  
Treatments were applied and cells were then placed in hypoxic or normoxic growth 
conditions for 48 hours.  Following treatment, cells were trypsinized and washed with 
PBS in preparation for flow cytometry. Cells were stained with the necrosis marker 7-
AAD (Biolegend®, 420404) and the apoptosis marker phycoerythrin-conjugated 
Annexin-V (Biolegend®, 640908) and analyzed using the Cytomics FC500 flow 
cytometer (Beckman Coulter, Mississauga, ON). Heat-killed samples singly stained for 
each marker and doubly stained for both markers served as positive controls for 
compensation analysis. Cells identified as viable were those negative for both Annexin-V 
and 7-AAD, as compared to the gated normoxic control samples. 
2.7 XTT Cytotoxicity Assay 
Pre-assay optimization was performed according to manufacturer protocol (ATCC, 30-
1011K) which allowed for identification of ideal seeding density and ideal reagent 
incubation time.  In 96-well plates, 786-O, 769-P and 786-O VHL+ cells were plated at 1 
x 10
4
 cells/mL, whereas Caki-1 and HK-2 cells were plated at 5 x 10
4
 cells/mL.  
Following plating, cells were allowed to adhere overnight before addition of treatment 
and growth under either normoxia or hypoxia. Cells were treated for 44 hours before 
addition of XTT Reagent to growth media for the remainder of the 48 hour incubation.  
Plates were read by a spectrophotometer at 660 nm, for measurement of non-specific 
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absorbance, and again at 475 nm for measurement of metabolic activity.  Wells were also 
blanked against growth media without cells or drug added.  Data was then normalized to 
the normoxic control after converting all final readings to positive values. 
2.8 ATP Quantitation Assay 
Cells were seeded into 24-well plates (3 x 10
5
 cells per well) and allowed to reach 90% 
confluency.  Treatments were applied and cells were then placed in normoxic or hypoxic 
growth conditions for 6 hours.  Growth media was aspirated, cells were washed twice 
with PBS and boiling ddH2O was used to lyse cells.  Cell lysate was transferred to 
Eppendorf tubes and centrifuged at 4 °C and 10,000 x g for 10 minutes.  The 
concentration of ATP in each sample was then quantified using Molecular Probes’ ATP 
Determination Kit (Invitrogen, A22066) which employs a luciferin/luciferase 
bioluminescence system.  Samples were quantified relative to ATP standard solutions 
using the luminometer function on the Synergy H4 Hybrid Multi-Mode Microplate 
Reader (Biotek Instruments, Winooski, VT), use of which was generously afforded by 
Dr. John McCormick (Western University, London, ON).  Luminometer readouts were 
blanked and converted to ATP concentrations using the curve generated by ATP 
standards.  ATP concentrations were normalized to protein concentrations for each 
sample after protein concentration was quantified using a Bradford protein assay (Bio-
Rad, 500-0006) and BSA standards. 
2.9 Avian Xenograft Vascularization Model 
2.9.1 Lentiviral Infection 
Four RCC cell lines (Caki-1, 769-P, 786-O, and 786-O VHL+) were seeded and grown to 
50-60% confluency.  Cells were inoculated with ZsGreen lentiviral vector containing a 
gene for extreme green fluorescent protein (EGFP) and a puromycin resistance gene for 
pooled clone selection.  Two days following infection, EGFP-expressing cells were 
selected for using 1-2 μg/mL of puromycin, depending on the cell line.  Puromycin was 
removed from growth medium following 2 weeks of sub-culturing. 
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2.9.2 Avian Chorioallantoic Membrane Xenografting 
Fertilized chicken eggs were incubated at 37°C in humidified, non-sterile conditions for 
three days before being cracked and deposited into individual plastic trays.  Embryos 
were placed back in the incubator and were ready for introduction of cancer cells after 
another six days of incubation.  On day 9 post-fertilization (pf), a filter paper disc 7 mm 
in diameter was placed onto the CAM near large oxygenated blood vessels and 
subsequently ripped off to remove the upper-most layers of the CAM. Ten microliters of 
a 1:1 suspension of EGFP-expressing cancer cells in BD Matrigel™ were then implanted 
on top of this exposed area, and tumours were given two days to establish themselves 
within the tissue. 
2.9.3 Xenograft Treatment and Processing 
At 2 days post-implantation, tumours that had successfully begun recruiting blood vessels 
were randomly sorted into four groups.  Intravascular injections of 50 µL of either:  i) 20 
mM HA, ii) 10 mM LC, iii) 20 mM HA + 10 mM LC or iv) PBS vehicle control were 
administered daily on days 11 pf through 14 pf.  On day 15 pf, embryos were 
intravascularly injected with 75 μL of 0.5 mg/mL rhodamine-labelled lens culinaris 
agglutinin (rhodamine-LCA; Vector Laboratories, RL-1042) to fluorescently label 
vasculature for subsequent analysis prior to harvesting tumours from the CAM.  As a 
control, 4 PBS-treated tumours were harvested and analyzed without rhodamine-LCA 
injection. Tumours were washed in PBS then fixed in 10% neutral buffered formalin 
containing 30% sucrose for a minimum of 1 week.  Tumours were then embedded in 
Optimal Cutting Temperature (OCT) compound and stored at -80°C until sectioning.  
Using a CM30505 Cryostat (Leica, Concord, ON), ten 10 μm sections were obtained 
from various depths of each tumour, with the plane of sectioning running parallel to the 
surface of the once-surrounding CAM.   
2.9.4 Quantification of Tumour Size 
Fluorescence stereoscope images of tumours were obtained at 20X magnification using 
the AX10 Zoom V.16 stereoscope (Zeiss, Toronto, ON) before tumours were harvested 
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from the CAM.  The cross-sectional area of stereoscope tumour images was measured 
using the hand trace tool in ImageJ Software. 
2.9.5 Quantitation of Vascularization 
Sectioning (Carl Postenka) and imaging/quantitation (Eric Sonke) of tumours were 
performed by separate individuals and both were performed in a blinded fashion.  
Sections were imaged using the Fluoview FV1200 confocal laser scanning microscope 
(Olympus, Toronto, ON) and the number of rhodamine-LCA positive blood vessels in 
each section was visually quantified.   
2.10 Human Tissue Microarray Analysis 
Three tissue biopsies were taken from 49 patients who underwent surgical procedures at 
L’Université de Montréal for the removal of renal masses.  Two biopsies were from 
diseased tissue and the third was from surrounding healthy tissue.  Acquisition and 
processing of formalin-fixed, paraffin-embedded samples was performed by personnel of 
Dr. Jean-Baptiste Lattouf (L’Université de Montréal, Montréal, QC) and samples were 
probed for CBS (rabbit anti-human CBS, Novus Biologicals, NBP1-33518) and CSE 
(rabbit anti-human CSE, ProteinTech, 12217-1-AP).  Digital images of stained tissue as 
well as patient information were sent from the Lattouf lab to the Sener lab.  Blinded 
scoring of antibody staining was performed by Eric Sonke using a system advised by Dr. 
Aaron Haig (Western University, London, ON).  Using a scale of 0-3, samples were 
scored on the degree of both diffuse and localized expression.  Correlation analysis 
relating protein expression to Fuhrman grade and tumour size were also performed. 
2.11 Statistical Analyses 
All statistical analyses were performed using GraphPad Prism v6.05 software.  Figures 
displaying representative data of one independent experiment show standard deviation of 
the mean.  Figures displaying data of multiple independent experiments show standard 
error of the mean.  Results from one-way ANOVA were further subjected to Tukey’s 
multiple comparisons test due to unequal sample sizes between groups.  Results from 
two-way ANOVA were further subjected to Sidak’s multiple comparisons test (to 
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optimize power), Tukey’s multiple comparisons test (in cases of unequal sample sizes) 
and Dunnett’s multiple comparisons test (when comparing to an identified control). 
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3. Results 
3.1 Objective I – Is Endogenous Production of H2S 
Enhanced in VHL-deficient ccRCC Cell Lines? 
3.1.1 Levels of H2S are increased in VHL-deficient ccRCC cell 
lines 
To address whether baseline H2S production is increased in VHL-deficient ccRCC, 
endogenous levels of H2S were measured in two VHL-deficient ccRCC cell lines (786-O 
and 769-P) and compared to a VHL WT ccRCC cell line (Caki-1) and a nonmalignant 
renal cell line (HK-2).  Accumulation of intracellular H2S was tracked over 15 hours 
using a fluorescent H2S-specific probe in combination with live-cell imaging (Figure 3).  
It was found that significant accumulation of H2S occurred in HK-2 cells (p < 0.001), 
786-O cells (p < 0.0001) and 769-P cells (p < 0.0001) over 15 hours, though not in Caki-
1 cells (p > 0.05; Figure 3A).  When compared to HK-2 cells, the accumulation of H2S in 
786-O and 769-P cells after 15 hours was significantly greater (p < 0.0001), while the 
accumulation of H2S in Caki-1 cells was significantly lower (p < 0.05) (Figure 3A, 1B).  
Accumulation of H2S in the VHL-deficient ccRCC cell lines after 15 hours was also 
significantly greater (p < 0.0001) than in the VHL WT Caki-1 cells (Figure 3A). 
In an attempt to implicate VHL deficiency in the accumulation of H2S, a functional allele 
of VHL was reintroduced into 786-O cells to partially restore its function.  Endogenous 
levels of H2S were then measured using the methylene blue assay and compared to 
unmolested 786-O cells, HK-2 cells and heat-killed control cells (Figure 4).  Re-
introduction of VHL into 786-O cells was unable to bring levels of H2S back down to 
baseline (Figure 4).  Detectable levels of H2S were observed in heat-killed cells, which 
highlights the non-specificity of this assay. 
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Figure 3. Baseline endogenous H2S production is greater in VHL-deficient ccRCC 
cell lines than in VHL WT malignant and non-malignant renal cell lines. Cells were 
seeded into 96-well plates and allowed to reach 90-100% confluency.  A cell-permeable 
probe that reacts specifically with H2S to fluoresce green was then either added (probe), 
or not added (no probe), to growth media and cells were imaged every hour for 15 hours.  
Following imaging, the number of fluorescent “hits” was normalized to cell confluency 
for each well and each time point, resulting in a normalized probe count which was then 
averaged (n = 3, error bars represent standard deviation of the mean).  Results are 
representative of 3 independent experiments (n = 9 total).  One-way ANOVA with 
Tukey’s multiple comparisons test was used to asses statistically significant differences 
between groups (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).  (A) (i) VHL 
mutation status of nonmalignant renal cells (HK-2) and ccRCC cell lines (Caki-1, 769-P, 
786-O). Statistically significant changes in endogenous H2S production over time 
(between 0 hours and 15 hours) in each cell line.  Statistically significant differences in 
endogenous H2S production between cell lines.  (B)  Representative images of enhanced 
endogenous H2S production in 786-O cells as compared to HK-2 cells. 
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Figure 4. Effect of VHL knock-in on endogenous H2S production in 786-O cells, as 
measured by methylene blue assay.  The methylene blue assay was used to compare 
endogenous H2S production in heat-killed cells (dead cells), non-malignant renal cells 
(HK-2), VHL-deficient ccRCC cells (786-O), and 786-O cells with VHL knocked-in 
through lentiviral transfection.   One-way ANOVA with Tukey’s multiple comparisons 
test revealed a lack of statistically significant differences between groups; n = 4 per cell 
line (n = 1 for dead cells).   
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3.1.2 VHL-deficient ccRCC cell lines do not display increased 
expression of CBS, CSE, or MPST 
It was hypothesized that VHL inactivation leads to increased expression of the H2S-
producing enzymes CBS, CSE and/or MPST, which in turn leads to increased cellular 
levels of H2S.  To answer this question, western blot analysis of CBS, CSE and MPST 
was performed to determine baseline expression of these enzymes in HK-2, Caki-1, 786-
O and 769-P cell lines (Figure 5).  There were no significant differences in baseline 
normoxic expression of CBS, CSE, nor MPST (Figure 5).  There was no clear trend to 
suggest that VHL inactivation leads to aberrant upregulation of endogenous H2S-
producing enzymes. 
To determine whether expression of CBS, CSE and/or MPST is regulated by hypoxia 
through mechanisms not involving VHL/HIF-1/2α, the same cell lines were grown in 
hypoxia for 6, 12 and 24 hours and protein extracted for further western blot analysis 
(Figure 6).  When compared to normoxic controls, expression of CBS, CSE, and MPST 
did not significantly increase under hypoxia in any of the cell lines (Figure 6). 
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Figure 5. Baseline normoxic expression of H2S-producing enzymes is unaltered in 
VHL-deficient ccRCC cell lines when compared to malignant and non-malignant 
VHL WT renal cell lines.  Protein was isolated from 80-90% confluent cell cultures 
grown in normoxia (21% O2) using RIPA buffer.  SDS-PAGE was carried out on 40-50 
μg of whole cell lysate using 10-12% poly-acrylamide gels and western blots were 
performed using PVDF membranes.  Blots were probed for (A) CBS (63 kDa), (B) CSE 
(45 kDa) and (C) MPST (33 kDa) while β-actin (43 kDa) served as a loading control 
against which protein expression was normalized. Expression of CBS, CSE and MPST in 
renal cancer cell lines (Caki-1, 786-O, 769-P) was normalized to expression of these 
same enzymes in the non-malignant renal epithelial cell line HK-2.  Error bars represent 
standard error of the mean (SEM), n = 3. Blots shown are representative of all three blots.  
One-way ANOVA and Tukey’s multiple comparisons test revealed no statistically 
significant differences in CBS, CSE nor MPST expression between cell lines.  
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Figure 6. Hypoxic induction of H2S-producing enzymes in malignant, and non-
malignant renal cell lines.  Protein was isolated from 80-90% confluent cell cultures 
grown in normoxia (N; 21% O2) or hypoxia (1% O2) for 6, 12 or 24 hours (H-6, H-12, H-
24) using RIPA buffer.  SDS-PAGE was carried out on 40-50 μg of whole cell lysate 
using 10-12% poly-acrylamide gels and western blots were performed using PVDF 
membranes.  Hypoxic induction of CBS (63 kDa), MPST (33 kDa) and CSE (45 kDa) 
was evaluated in (A) HK-2, (B) Caki-1, (C) 786-O and (D) 769-P cell lines.  β-actin (43 
kDa) served as a loading control against which protein expression was normalized. Error 
bars represent standard error of the mean (SEM), n = 3. Blots shown are representative of 
all three blots.  One-way ANOVA and Tukey’s multiple comparisons test revealed a lack 
of statistically significant differences in CBS, CSE and MPST expression between 
treatments in all cell lines. 
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To more thoroughly investigate the relationship between VHL function and hypoxic 
induction of CBS, CSE and MPST, western blot analysis comparing expression of CBS, 
CSE and MPST in 786-O and 786-O VHL+ cells under normoxia and hypoxia was 
performed (Figure 7).  When VHL function was restored to 786-O cells, expression of 
CBS, CSE and MPST did not change (Figure 7).  Interestingly, the hypoxic expression 
profile of CSE (ratio of high molecular weight band to low molecular weight band) was 
significantly altered following knock-in of VHL into 786-O cells (Figure 7B).  Successful 
knock-in of functional VHL (VHL
wt
) was also confirmed via western blot analysis 
(Figure 7C). 
 
48 
 
 
   
   
   
   
   
   
49 
 
Figure 7. Normoxic expression and hypoxic induction of H2S-producing enzymes in 
wild-type 786-O cells (786-O) and VHL knock-in 786-O cells (786-O VHL+).  Protein 
was isolated from 80-90% confluent cell cultures grown in normoxia (21% O2) or 
hypoxia (1% O2) for 15 hours using RIPA buffer.  SDS-PAGE was carried out on 40-50 
μg of whole cell lysate using 10-12% poly-acrylamide gels and western blots were 
performed using PVDF membranes.  Normoxic expression (A) or hypoxic induction (B) 
of CBS (63 kDa), MPST (33 kDa) and CSE (45 kDa) was evaluated in 786-O and 786-O 
VHL+ cell lines.  Validation of VHL
wt
 (20 kDa) knock-in was performed under both 
normoxia and hypoxia (C).  Protein levels were expressed relative to β-actin (43 kDa), or 
as a ratio of top band: bottom band (CSE, MPST) or as a ratio of functional protein:non-
functional protein (VHL) in instances where doublet bands are presented. Error bars 
represent standard error of the mean (SEM), n = 3. One-way ANOVA and Tukey’s 
multiple comparisons test indicate statistically significant differences (p < 0.05) where 
indicated (*). 
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3.2 Objective II – Does Endogenous H2S Production 
Contribute to the Proliferation, Metabolism and Survival 
of ccRCC Cell Lines? 
3.2.1 Endogenous H2S production can be targeted, though not 
stimulated, in VHL-deficient ccRCC cell lines 
The dual CBS/CSE inhibitor HA, the CSE inhibitor PAG and the substrate for 
endogenous H2S production LC were administered to HK-2, Caki-1, 786-O and 769-P 
cell lines to determine if they could influence baseline H2S production (Figure 8).  Using 
the fluorescent H2S-specific probe it was found that accumulation of H2S in HK-2 cells 
significantly (p < 0.0001) increased over time when LC (blue) was added to growth 
media (Figure 8A) and that this increase in H2S was significantly greater than the 
increase observed in untreated cells (Figure 8B).  LC was able to evoke a similar 
response in VHL WT Caki-1 cells (Figure 8A, B).  However, in the VHL-deficient 
ccRCC cell lines, treatment with LC did not increase endogenous H2S production to the 
same degree, as a result of increased baseline levels (Figure 8A, B). 
As a result of their elevated baseline production of H2S, VHL-deficient ccRCC cell lines 
were much more susceptible to inhibition with HA when compared to non-malignant 
HK-2 cells and VHL WT Caki-1 cells (Figure 8, red).  There was no significant 
accumulation of H2S in HK-2 cells over 15 hours when cultured in the presence of HA 
(Figure 8A) and levels of H2S in HA-treated cells were significantly (p < 0.05) lower than 
in untreated cells (Figure 8B).  The reductions in H2S upon HA treatment were also 
significant in 769-P cells (p < 0.0001; Figure 8B) and 786-O cells (p < 0.0001; Figure 
8Biv).  Treatment of all cell lines with a combination of HA and LC could significantly 
increase production of H2S when compared to treatment with HA alone (Figure 8, green).  
Treatment with the CSE inhibitor PAG did not significantly decrease endogenous H2S 
production (data not shown). 
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Figure 8.  Inhibition of endogenous H2S production reduces elevated levels of H2S in 
VHL-deficient ccRCC cell lines.  Cells were seeded into 96-well plates and allowed to 
reach 90-100% confluency.  A cell-permeable probe that reacts specifically with H2S to 
fluoresce green was then added (or not added; ie. no probe), to growth media.  At the 
same time, cells were treated with either PBS vehicle (control; black) an inhibitor of 
endogenous H2S synthesis (hydroxylamine (HA); 1 mM; red), the substrate for 
endogenous H2S synthesis (L-cysteine (LC); 5 mM; blue) or a combination of the two (1 
mM HA + 5 mM LC; green).  Cells were imaged every hour for 15 hours and background 
fluorescence was compensated for using thresholding.  Following compensation, the 
number of fluorescent “hits” was normalized to cell confluency for each well and each 
time point, resulting in a normalized probe count which was then averaged (n = 3, error 
bars represent standard deviation of the mean).  Results are representative of 3 
independent experiments (n = 9 total).  One-way ANOVA with Tukey’s multiple 
comparisons test was used to asses statistically significant differences between groups (* 
p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).  (A) Statistically significant 
changes in endogenous H2S production over time (between 0 hours and 15 hours) were 
determined for each treatment in HK-2, Caki-1, 769-P and 786-O cells.  (B) Statistically 
significant differences in endogenous H2S production between treatments were 
determined in each cell line.   
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3.2.2 Endogenous H2S production contributes to the proliferation 
of ccRCC cell lines 
Cells were treated with HA and cell confluency was tracked over 15 hours using live-cell 
imaging to determine whether endogenous H2S production plays a role in mediating cell 
growth (Figure 9).  HA treatment did not significantly restrict the growth of HK-2 cells 
(Figure 9).  Significant (p < 0.05) restriction of cell growth was observed in Caki-1 cells, 
769-P cells and 786-O cells, though not in 786-O VHL+ cells (Figure 9).  While higher 
concentrations of HA (1 mM) were cytotoxic to ccRCC cell lines, lower concentrations 
of HA (0.1 mM) actually slightly stimulated cell growth (data not shown).  As such, there 
is a narrow range in which inhibition of endogenous H2S production can restrict cell 
growth.  There was no clear relationship between VHL inactivation, and reliance on H2S 
for cell growth (Figure 9). 
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Figure 9.  Inhibition of endogenous H2S production attenuates proliferation of 
ccRCC cell lines.  Cells were seeded into 96-well plates and allowed to reach 40-60% 
confluency.  Cells were treated with either PBS vehicle (control; black) or an inhibitor of 
endogenous H2S synthesis (hydroxylamine (HA); 0.5 mM; red).  Cells were imaged 
every hour for 12 hours and phase confluency was measured.  (A) Following imaging, 
percentage change in cell confluency was determined for each well and averaged for each 
time point (n = 3, error bars represent standard deviation of the mean).  Results are 
representative of 2 independent experiments (n = 6 total).  Multiple t-tests were used to 
asses statistically significant differences between groups at T = 12 hours (* p < 0.05).  
(B) Representative images depicting inhibition of cell proliferation following 12 hour 
treatment with HA.   
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
3.2.3 Endogenous H2S production contributes to the survival of 
ccRCC cell lines 
Cells were treated with HA and PAG to determine whether loss of endogenous H2S 
production impacts 48 hour cell survival under normoxic and hypoxic conditions, as 
determined by Annexin-V-PE and 7-AAD detection (Figure 10).  Under normoxic 
conditions all ccRCC cell lines were found to be significantly (p < 0.05) more susceptible 
to treatment with HA than HK-2 cells (Figure 10A,C).  Caki-1 and 786-O cell lines were 
also significantly (p < 0.05) more susceptible to treatment with HA than HK-2 cells under 
hypoxic conditions, however 769-P cells were not (Figure 10A).  The reduction in 
hypoxic viability of HK-2 cells was significantly (p < 0.05) greater than the reduction in 
normoxic viability (Figure 10B), while the opposite was true of the ccRCC cell lines 
(Figure 10D).  Inhibition of CSE alone, through use of the inhibitor PAG, proved to be 
less effective in reducing viability than inhibition of CBS and CSE through use of the 
inhibitor HA (Figure 10D).  The only cell line to display significant declines in viability 
following PAG treatment was the ccRCC cell line 769-P (Figure 10D). 
When treated with a combination of HA and LC, the VHL-deficient ccRCC cell lines 
769-P and 786-O displayed significant (p < 0.05) restoration of viability when compared 
to treatment with HA alone (Figure 10E).  The same could not be said of the VHL WT 
Caki-1 cell line. 
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Figure 10. Inhibition of endogenous H2S production selectively kills ccRCC cells 
over non-malignant renal cells.  Cells were treated for 48 hours with inhibitors of 
endogenous H2S production hydroxylamine (HA) and propargyl glycine (PAG) and/or 
the substrate for endogenous H2S production L-cysteine (LC) in normoxic (21% O2) or 
hypoxic (1% O2) growth conditions.  Cell culture viability was determined via detection 
of Annexin-V-PE and 7AAD using flow cytometry and quantified relative to the 
untreated, normoxic cells within each experimental trial.  Error bars represent standard 
error of the mean (SEM). Two-way ANOVA with Dunnett’s multiple comparisons test 
was used to asses significant differences between groups (i.e. normoxic control vs. 
hypoxia control; †; p < 0.05).  Two-way ANOVA with Sidak’s multiple comparisons test 
was used to assess significant differences between treatments within groups (i.e. 
normoxic control vs. normoxic 4 mM HA; *; p < 0.05).  (A) ccRCC cell lines are more 
susceptible to treatment with HA than non-malignant HK-2 cells, n = 6-9.  (B) HK-2 cells 
are susceptible to treatment with HA, however hypoxic viability is impacted more-so 
than normoxic viability, n = 6.  (C) Representative flow cytometry dot plots illustrating 
changes in normoxic viability of cell lines following treatment with 4 mM HA, as 
quantified in (A).  (D) Differential susceptibility of ccRCC cell lines to treatment with 
HA and PAG (Caki-1, n = 6-8; 769-P, n = 6-12; 786-O, n = 6-10).  (E) VHL-deficient 
ccRCC cell lines treated with HA and LC simultaneously display attenuated declines in 
viability (Caki-1, n = 3-6; 769-P, n = 3-8; 786-O, n = 4-6). 
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3.2.4 Endogenous H2S production contributes to the metabolism 
of ccRCC cell lines 
To determine if declines in viability upon inhibition of endogenous H2S production were 
the result of deficits in metabolic activity, the XTT cytotoxicity assay was used to 
measure alterations in metabolic activity after 48 hour treatment (Figure 11).  It was 
observed that the VHL-deficient cell lines 786-O and 769-P suffered significant declines 
in metabolic activity upon treatment with HA (p < 0.05) while the VHL wild-type cell 
lines HK-2, Caki-1 and 786-O VHL+ did not (Figure 11).  As with the viability assays, 
combination treatment with HA and LC resulted in significant (p < 0.05) restoration of 
hypoxic metabolic activity compared to HA treatment alone in the VHL-deficient ccRCC 
cell lines 786-O and 769-P (Figure 11).  Combination treatment with HA and LC also 
resulted in significant (p < 0.05) differences between normoxic and hypoxic viability in 
all ccRCC cell lines, but not HK-2 cells (Figure 11). 
The XTT assay measures mitochondrial metabolism based on the activation of coenzyme 
Q by NADH and other electron donors.  In order to quantitate how H2S production may 
be contributing to forms of metabolism that do not rely on electron transport, total ATP 
was measured following 6 hour treatments administered under normoxia and hypoxia 
(Figure 12).  Unexpectedly, hypoxic ATP production was significantly (p < 0.05) higher 
than normoxic ATP production for HK-2 cells (Figure 12).  Inhibition with HA 
significantly (p < 0.05) decreased normoxic and hypoxic ATP production in all HK-2 
cells, 786-O cells and 786-O VHL+ cells (Figure 12).  Combined treatment with HA and 
LC could not restore ATP production in any of the cell lines, contrary to results of the 
XTT assay (Figure 12). 
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Figure 11.  Inhibition of endogenous H2S production reduces overall metabolic 
activity of ccRCC cell lines. Metabolic activity was assessed via the XTT assay 
following 48 hour treatment with hydroxylamine (HA), L-cysteine (LC) or a combination 
of both.  Values are presented as relative to the untreated, normoxic cells within each 
experimental trial.  Error bars represent standard error of the mean (SEM).  HK-2 (n = 6), 
Caki-1 (n = 6), 786-O VHL+ (n = 6), 769-P (n = 5-6), 786-O (n = 5-6).  Two-way 
ANOVA with Dunnett’s multiple comparisons test was used to asses significant 
differences between groups (normoxic control vs. hypoxia control; †; p < 0.05).  Two-
way ANOVA with Sidak’s multiple comparisons test was used to assess significant 
differences between treatments within groups (normoxic control vs. normoxic 4 mM HA; 
*; p < 0.05). 
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Figure 12.  Inhibition of endogenous H2S production reduces ATP production in 
malignant and non-malignant renal cell lines.  Total cellular ATP was assessed using a 
luciferin/luciferase-based assay following 6 hour treatment with hydroxylamine (HA), L-
cysteine (LC) or a combination of both.  ATP concentration was normalized in each 
sample using protein concentration and then averaged (n = 3, error bars represent 
standard deviation of the mean).  Results are representative of 2 independent experiments 
(n = 6 total).  Two-way ANOVA with Dunnett’s multiple comparisons test was used to 
asses significant differences between groups (normoxic control vs. hypoxia control; †; p 
< 0.05).  Two-way ANOVA with Sidak’s multiple comparisons test was used to assess 
significant differences between treatments within groups (normoxic control vs. normoxic 
4 mM HA; *; p < 0.05). 
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3.3 Objective III – Does Endogenous H2S Production 
Contribute to the Neovascularization of ccRCC 
Xenografts? 
3.3.1 Inhibition of endogenous H2S production restricts the 
neovascularization of ccRCC xenografts 
H2S is known to participate in paracrine angiogenic signalling and has been shown to 
play a role in the vascularization of other cancers.  To investigate the effects of 
endogenous H2S production on the vascularization of ccRCC tumours, the chick 
chorioallantoic membrane (CAM) was used as a vascular structure for xenograft 
implantation of ccRCC cell lines.  Cell lines were manipulated to express EGFP and 
chick vasculature was labelled with rhodamine-labelled lens culinaris agglutinin 
(rhodamine-LCA) such that the number of intratumoural blood vessels could be 
quantified using fluorescent microscopy. Treatments were injected IV for four 
consecutive days following two days of initial tumour growth and then harvested, 
sectioned and imaged (Figure 13). 
Treatment with HA was able to significantly (p < 0.05) decrease the vascularization of 
the VHL-deficient 786-O and 769-P xenografts while the same treatment had no effect on 
the vascularization of VHL wild-type Caki-1 xenografts (Figure 13).  Treatment with LC 
was able to significantly (p < 0.05) increase the number of intratumoural blood vessels 
(Figure 13A) and also appeared to dilate blood vessels (Figure 13B).  When 786-O and 
769-P xenografts were treated with a combination of HA and LC simultaneously, the 
decline in vascularization observed with HA treatment alone was attenuated (Figure 13).  
Knock-in of VHL into the 786-O cell line not only decreased overall vascularization of 
untreated xenografts, but also appeared to eliminate the cells’ sensitivity to HA and LC 
treatment (Figure 13). 
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Figure 13.  Systemic inhibition of endogenous H2S production with hydroxylamine 
(HA) reduces the vascularization of VHL-deficient ccRCC xenografts.  ccRCC cell 
lines were xenografted into the CAM of 9-day old chicken embryos and given 2 days to 
establish themselves within the surrounding tissue.  Embryos were then systemically 
treated once a day for 4 days with 50 μL of 20 mM hydroxylamine (HA), 10 mM L-
cysteine (LC) or a combination of both (HA + LC) through intravascular microinjection.  
Prior to harvest, embryos were systemically injected with rhodamine-conjugated lens 
culinaris agglutinin (rhodamine-LCA) to label all chick vasculature.  (A) The number of 
rhodamine-LCA-positive blood vessels present in each field of view shot was counted 
manually following confocal imaging at 200X total magnification.  Error bars represent 
standard error of the mean (n ≥ 30 per treatment). One-way ANOVA with Dunnet’s 
multiple comparisons test was used to assess statistical significance of treatments 
compared to PBS vehicle control (*; p < 0.05). (B) Representative images of data 
depicted in (A).  Rhodamine-LCA-positive blood vessels (red) are seen in close 
proximity to EGFP-expressing RCC cells (green).  Scale bar represents 100 μm. 
 
 
 
 
 
 
 
 
 
 
 
65 
 
3.3.2 Inhibition of endogenous H2S production restricts the growth 
of ccRCC xenografts 
Similar trends were observed when analyzing the effect of H2S production on tumour 
growth as measured by cross-sectional area of whole tumours prior to harvest (Figure 
14).  HA treatment was able to significantly (p < 0.05) decrease the size of 769-P 
xenografts, but not the size of 786-O xenografts (Figure 14).  Conversely, HA treatment 
had no effect on the cross-sectional area of VHL WT Caki-1 and 786-O VHL+ 
xenografts (Figure 14).  As with vascularization, treatment with HA and LC 
simultaneously was able to attenuate the decrease in size in 786-O and 769-P xenografts 
(Figure 14).  Qualitative inspection of tumours revealed that HA treatment also resulted 
in necrotic and dysmorphic tumours (Figure 14B). 
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Figure 14.  Systemic inhibition of endogenous H2S production with hydroxylamine 
(HA) restricts the growth of VHL-deficient ccRCC xenografts.  ccRCC cell lines 
were xenografted into the CAM of 9-day old chicken embryos and given 2 days to 
establish themselves within the surrounding tissue.  Embryos were then systemically 
treated once a day for 4 days with 50 μL of 20 mM hydroxylamine (HA), 10 mM L-
cysteine (LC) or a combination of both (HA + LC) through intravascular microinjection.  
Prior to harvest, fluorescent stereoscope images were obtained for each tumour.  (A) The 
cross-sectional area of stereoscope images (20X) of each tumour was measured using 
ImageJ software.  Error bars represent standard error of the mean (n ≥ 10 per treatment).  
One-way ANOVA with Dunnet’s multiple comparisons test was used to asses statistical 
significance of treatments compared to PBS vehicle control (*; p < 0.05).  (B) 
Representative images of data depicted in (A).  zsGreen expression (green) was used to 
identify RCC cells.  Scale bar represents 1 mm. 
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3.4 Objective IV – Is Endogenous H2S Production 
Enhanced in Human ccRCC Tumours? 
3.4.1 Expression of CBS or CSE is not upregulated in human 
ccRCC tumours 
In an attempt to link increased endogenous H2S production to the progression of actual 
ccRCC tumours, patient-matched renal biopsies of healthy and diseased tissue were 
probed for CBS and CSE.  Antibody staining was scored on a scale of 0-3 for intensity of 
localized (punctate dots) and diffuse (hazy, non-specific) expression.  When all tumours 
were analyzed together – without being sub-classified as benign, malignant, non-ccRCC 
or ccRCC – diseased tissue had significantly (p < 0.0001) lower diffuse expression of 
both CBS and CSE, whereas localized expression was maintained (Figure 15A).  The 
same trend applied when tumour classes of benign (Figure 15B), malignant (Figure 15C) 
and ccRCC (Figure 15D, E) were analyzed individually.  
3.4.2 Expression of CBS or CSE is not correlated with Fuhrman 
grade or tumour size 
To determine whether expression of CBS and CSE were in some way correlated with 
prognostic factors of ccRCC, correlation analyses were performed for staining 
intensity/Fuhrman grade, as well as staining intensity/tumour size.  When localized 
expression of CBS and CSE was plotted against Fuhrman grade, no significant 
correlation was apparent (CBS: r = -0.044; CSE: r = 0.272).  Diffuse expression of CBS 
and CSE was also not correlated with Fuhrman grade (CBS: r = 0.085; CSE r = -0.043).  
There was also no correlation between tumour volume and diffuse/localized expression 
of CBS (diffuse: r = -0.153; localized: r = -0.135) and CSE (diffuse: r = 0.008; localized: 
r = 0.171).  Clinical details of patient samples are available in Appendix A. 
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Figure 15.  Diffuse and localized expression patterns of CBS and CSE in human 
renal tumour samples.  Patient-matched biopsies from healthy (normal, n = 1 per 
patient) and diseased (tumour, n = 2 per patient) renal tissue were fixed, paraffin 
embedded into tissue microarray blocks, sectioned and immunohistochemically probed 
for both CBS and CSE.  Images of stained sections were scored for both intensity of 
diffuse expression (diffuse) and intensity of localized expression (localized) on a scale of 
0-3 in a blinded fashion.  Error bars represent standard error of the mean (SEM).  One-
way ANOVA with Tukey’s multiple comparisons test was used to asses statistically 
significant differences between groups (** p < 0.01; *** p < 0.001; **** p < 0.0001).  
Data were categorized by tumour type: (A) All tumours, n = 49 normal sections, n = 98 
tumour sections; (B) Benign tumours, n = 7 normal sections, n = 14 tumour sections; (C) 
Malignant tumours, n = 42 normal sections, n = 84 tumour sections; (D) Clear-cell 
tumours, n = 27 normal sections, n = 54 tumour sections. (E)  Representative expression 
patterns of CBS and CSE in normal and ccRCC tissue samples.  Note in ccRCC samples 
the loss of diffuse CBS and CSE expression but maintenance of intensely staining puncta.  
Scale bar represents 100 μm. 
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4. Discussion 
4.1 Relation to Initial Hypothesis 
In order for something to accumulate, the rate of its production must exceed the rate of its 
removal.  Our understanding of endogenous H2S production by CBS, CSE and MPST is 
in its infancy, and our understanding of H2S removal via mitochondrial oxidation is even 
less well-developed.  It was originally hypothesized that endogenous production of H2S 
would be increased in ccRCC cell lines lacking a functional copy of the VHL tumour 
suppressor, as a result of HIF-1/2α-mediated upregulation of H2S-producing enzymes.  
While levels of H2S were elevated in VHL-deficient ccRCC cell lines, it was not due to 
increased expression of the enzymes responsible for H2S production – CBS, CSE and 
MPST.  The most likely explanation for this result is that loss of VHL function and HIF-
1/2α accumulation results in decreased mitochondrial biogenesis and respiration (55), 
thus eliminating the primary mechanism of H2S removal – mitochondrial oxidation.  
Therefore, while VHL inactivation and HIF-1/2α accumulation does not influence H2S 
production by inducing expression of CBS, CSE and MPST, VHL inactivation and HIF-
1/2α accumulation likely influence H2S removal by decreasing overall mitochondrial 
activity. 
The efficacy of targeted therapies for cancer treatment lies in the cancer possessing some 
trait that non-malignant cells do not possess.  Targeted therapies that have been 
developed for treatment of ccRCC are clinically effective due to their ability to 
specifically target these traits with relatively mild adverse effects (42).  However, while 
specificity of action is desired with any treatment, it inherently limits the range of cellular 
processes that are subject to inhibition.  In the case of ccRCC, today’s clinical therapies 
are unable to concurrently target tumour cell growth/survival and the tumour’s 
angiogenic potential (11).  While the targeted approach has been shown to be a sound 
one, the identification of new targets that may be mediating multiple aspects of disease 
should continue to be pursued. 
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Here it has been shown that targeting the endogenous production of H2S can reduce the 
proliferation, survival, metabolic output, and angiogenic potential of ccRCC cell lines, 
with minimal effects on non-malignant cells treated in vitro and in vivo.  This presents 
endogenous H2S-production as a valuable target in ccRCC, which when inhibited restricts 
multiple facets of cancer progression. 
4.2 VHL, H2S and Oxygen Sensing 
The VHL tumour suppressor is a key component of the cellular response to hypoxic 
growth conditions.  Since O2 is essential for ATP production through oxidative 
phosphorylation, cells must rely on glycolysis for ATP production under hypoxic or 
anaerobic conditions.  Through evolution, eukaryotic cells have also come to realize that 
a drop in O2 concentration is usually due to disruption of blood supply, so hypoxic cells 
secrete factors to stimulate the growth and attraction of new blood vessels.  The shift in 
metabolism and angiogenic response under hypoxia are both mediated by VHL, and 
unintentional triggering of these responses occurs in the majority of ccRCC tumours as a 
result of complete loss of VHL function (16).  The perceived hypoxia, or pseudohypoxia 
of ccRCC tumours has been well-documented (14), however loss of VHL function alone 
does not lead to the formation of ccRCC tumours and holds no value as a prognostic 
indicator of disease (22,23). 
There is much evidence to support that endogenous H2S acts as an oxygen sensor in 
many eukaryotes, including humans, and as such it has many things in common with the 
VHL/HIF-1/2α pathway (62).  H2S is constantly being produced by cells throughout the 
body (64), and in turn it is removed by mitochondria in an oxygen-dependent fashion 
(122).  Thus under normoxia, mitochondrial oxidation of H2S is high and levels of H2S 
remain low, ensuring that oxidative phosphorylation can continue without being inhibited 
by H2S at Complex IV of the ETC (63,121).  However under hypoxia, mitochondrial 
oxidation of H2S is impaired and H2S accumulates within the cell where it can directly 
influence cell signaling through post-translational modification of proteins through 
cysteine (S)-sulfhydration (102).  S-sulfhydration of GAPDH increases its glycolytic 
activity by 700%, thus ensuring that the cell can satisfy its demand for ATP in the 
absence of oxidative phosphorylation (102).  H2S accumulation under hypoxia also 
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affects endothelial cells through paracrine S-sulfhydration of PDE5 and KATP channels 
which are necessary events in vasodilatory and angiogenic signalling pathways that aim 
to restore blood supply (107,108). 
If both the VHL/HIF-1/2α pathway and H2S production/oxidation pathway are 
mechanisms of sensing and responding to hypoxia, then surely ccRCC tumours can 
become pseudohypoxic when either pathway, or both pathways, become dysfunctional.  
In fact, loss of VHL function and HIF-1/2α accumulation in ccRCC may also be 
responsible for the loss of mitochondrial oxidation of H2S, which provides a link between 
these two oxygen-sensing pathways in ccRCC.  Baseline measurements of H2S were 
shown to be higher in VHL-deficient ccRCC cell lines than in VHL WT ccRCC cell 
lines.  This would suggest that these two pathways are linked.   Decreased mitochondrial 
biogenesis, respiration and overall O2 consumption has been reported in ccRCC through 
various mechanisms involving HIF-1/2α accumulation, which further supports this link 
(55,56). 
4.3 Crosstalk between HIF-1/2α and H2S 
There has been evidence to suggest that in addition to decreased mitochondrial oxidation 
of H2S under hypoxia, levels of H2S also increase under hypoxia as a result of HIF-1/2α-
mediated induction of CBS (99).  While there did not appear to be aberrant upregulation 
of CBS, CSE, nor MPST in VHL-deficient ccRCC cell lines, there was a slight (though 
not significant) decrease in CBS and CSE expression when VHL function was restored to 
786-O cells.  It is unlikely that such drastic differences in endogenous levels of H2S 
observed between VHL WT and VHL-deficient cell lines can be explained by this 
modest change in CBS and CSE expression.  However, it is possible that HIF-1/2α-
mediated control over CBS and CSE is contributing in some small way to increased 
production of H2S.  Perhaps hypoxic induction of CBS and CSE is of greater use in cells 
that display relatively low baseline normoxic expression of these enzymes, when 
compared to renal epithelial cells that display high baseline normoxic expression (86).   
HIF-1/2α transcription factors may not play an important role in regulating the expression 
of CBS, CSE and MPST, however that is not to say that HIF-1/2α doesn’t regulate the 
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activity of CBS, CSE and MPST.  Measurement of enzyme activity in cell lines with 
different HIF-1α and HIF-2α expression profiles was not undertaken here due to a lack of 
equipment required for such biochemical assays.  However, differences in relative 
expression of the upper and lower bands of CSE and MPST were observed in western 
blot analysis of 786-O cells with and without functional VHL.  While the changes that 
these bands represent in terms of protein structure and function have not been 
investigated, it is possible that they may represent differences in enzyme activity, or even 
differences in enzyme localization.  CSE has been shown to translocate to mitochondria 
in response to various stressors, and others have shown that this translocation/stress is 
associated with slight changes in the appearance of the band in western blots (123).  In 
contrast, there is also evidence to suggest that H2S being produced by CBS, CSE and 
MPST may reciprocally alter HIF-1/2α activity (143), which could have implications on 
how ccRCC progresses. 
As stated previously, loss of VHL function can result in tumours that overexpress HIF-1α 
and HIF-2α to varying degrees, leading to H1H2 and H2 tumours (24,26).  These two 
subsets of VHL-deficient ccRCC tumours have been shown to be unique with regards to 
their preferred metabolic and proliferative pathways due to the differences in how HIF-1α 
and HIF-2α interact with other oncogenes like c-MYC and MXI1 (24,55).  It is well 
accepted that one of the key steps in ccRCC progression is loss of VHL function, which 
results in VHL-deficient tumours with the H1H2 phenotype (24).  Recent evidence 
suggests that loss of HIF-1α – resulting in the more aggressive H2 phenotype – may be 
another key event in ccRCC progression, although the mechanism by which HIF-1α is 
lost is unknown (9,18,30).  Exogenous H2S has been shown to reduce both the 
translational expression, and the activity of HIF-1α (143), however this effect has been 
shown to be dependent on VHL function and mitochondrial activity (144).  Interestingly, 
H2S-mediated HIF-1α degradation also only occur under true hypoxic conditions – not in 
response to hypoxia-mimetics, nor in pseudohypoxic RCC cell lines (144).  There is also 
evidence that a reducing environment can enhance the stability of HIF-2α, although the 
effects of a reducing environment on HIF-1α stability were not investigated (145).  
Further investigation into whether increased levels of endogenous H2S plays a role in loss 
of HIF-1α in ccRCC is required. 
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4.4 H2S in ccRCC Proliferation, Metabolism and Survival  
There are dynamic relationships that exist between cell growth, proliferation, metabolism 
and survival.  On the surface these relationships may seem obvious – through 
metabolism, cells generate energy and molecules that are needed to grow in size, 
proliferate and survive in general (53).  It is only after considering the various trade-offs 
that exist between these variables that one realizes the complex decisions that cells make 
on a minute-to-minute basis.  For example, different growth factors stimulate different 
proliferative and metabolic pathways, which generate variable levels of ROS.  The degree 
of ROS production in turn affects the activity of these proliferative pathways and, if 
excessive, can induce a cell to undergo apoptosis.  These relationships become even more 
counter-intuitive in the context of cancer, where due to mutations, the cancer cell can no 
longer recognize the value on either side of the trade-off, and does not react the way a 
normal cell would (53). 
Here we showed that H2S production contributes to the enhanced proliferation observed 
in ccRCC cell lines, and targeting its production can slow, and even stop, proliferation.  
Exogenous H2S has been shown to play a role in the cell cycle entry and proliferation of 
colonocytes through increased production of NADPH, activation of mitogen-activated 
protein kinase and Akt signalling pathways, and inactivation of the cell-cycle inhibitor 
p21 (130,146). Likewise, inhibition of endogenous H2S synthesis can slow the 
proliferation of ovarian cancer and colon cancer cell lines (131,133).  It was observed 
here that the range of concentrations, as well as treatment time, at which the CBS/CSE 
inhibitor halted proliferation before becoming cytotoxic was small. As the length of 
treatment time and/or concentration of the inhibitor increased, loss of H2S production 
resulted in decreased metabolic activity, decreased ATP production, and ultimately 
apoptosis and necrosis.  Seeing as loss of H2S production was ultimately cytotoxic in 
ccRCC cell lines and not simply cytostatic, one is led to believe that it plays an important 
role in energy production.  As observed here, a slight decrease in H2S production results 
in a small deficit in energy production and influences the cell to stop dividing in order to 
maintain essential survival processes.  However, a greater decrease in H2S production 
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results in a significant deficit in energy production to the point where the cell can no 
longer maintain essential processes and dies. 
In this study, energy production – metabolism – was measured using two different assays 
– the XTT assay and total ATP quantitation.  The XTT assay measures metabolic activity 
by quantifying the turnover of electron carriers that donate electrons to coenzyme Q.  
This would include NADH, flavin adenine dinucleotide, and, in the context of H2S, SQR 
(122).  Here it was found that the VHL-deficient ccRCC cell lines not only produced 
higher levels of H2S than their VHL WT counterparts, but were also more susceptible to 
metabolic inhibition with HA.  Given the lack of mitochondrial respiration in VHL-
deficient ccRCC cell lines, it is likely that inhibiting H2S production resulted in a 
decrease in glycolytic activity, and decreased NADH production by LDH.  This is 
supported by results of the ATP assay, in which loss of H2S production drastically 
reduced both hypoxic and normoxic ATP levels.  Others have reported that H2S mediates 
its metabolic effects in cancer by donating electrons to the ETC through mitochondrial 
oxidation (131,133).  However if this was the case in ccRCC, one would have expected 
that metabolic inhibition would only have been achieved under normoxic conditions, 
seeing as mitochondrial oxidation requires oxygen (122).  This isolated decline in 
normoxic metabolism was not observed in the VHL-deficient cell lines, but was observed 
when VHL was reconstituted into 786-O cells. 
Results of the ATP assay did not entirely agree with results of the XTT assay.  HK-2 
ATP levels were significantly reduced upon HA treatment, however no significant 
difference was apparent in the XTT assay.  This could be due to the fact that the ATP 
assays were 6 hours in length whereas the XTT assays were 48 hours in length.  Also, 
H2S has been shown to reverse the flow of electrons through Complex I of the ETC, 
forcing Complex I to take electrons from coenzyme Q and reduce NAD
+
 into NADH 
(122).  This allows the cell to oxidize H2S before it becomes toxic, while at the same time 
keeping the pool of available NADH high.  In this way, H2S could still be contributing to 
ATP production in nonmalignant renal epithelial cells – as was seen here and elsewhere 
(122).  However, loss of H2S oxidation would not be apparent in an XTT assay since loss 
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of Complex I reversion would not change the level of coenzyme Q activation – coenzyme 
Q would just be oxidized by NADH instead of SQR. 
The XTT assay also showed that decreased metabolism upon HA treatment could be 
rescued in VHL-deficient cell lines when LC was also present in growth media.  This 
rescuing effect was not seen in the ATP assay, however it was observed in the flow 
cytometry viability assays.  In addition to its role in the ETC and metabolism, coenzyme 
Q also serves antioxidative functions within the plasma membrane, playing a role in the 
oxidative stress response (147).  Therefore, a positive signal in the XTT assay can also 
indicate increased antioxidative activity, increased resistance to oxidative stress, and 
improvement in survival.  It is known that the metabolic reprogramming in VHL-
deficient ccRCC helps to keep oxidative stress in check by rerouting certain glycolytic 
intermediates towards the production of NADPH (53).  NAD
+
 levels must also remain 
high in order for aerobic glycolysis to function (137), which is thought to be largely 
accomplished by LDH in ccRCC (55).  Recent evidence has shown that production of 
H2S in other cancers is a crucial component of the aerobic glycolysis energy circuit that 
reduces oxidative stress and contributes to ATP production by maintaining production of 
NAD
+
 (138,139).  Therefore, in helping to maintain the supply of NAD
+
 that fuels 
aerobic glycolysis in ccRCC, H2S may also ensure that production of the antioxidant 
NADPH also remains high. 
As has been seen in studies of ovarian cancer (133) and colon cancer (131), increasing 
concentration of inhibitors of CBS and CSE results in a steep drop off in ccRCC cell 
viability.  Interestingly, most of the cell lines investigated here were not susceptible to 
inhibition with PAG – which specifically inhibits CSE – despite the fact that all cell lines 
expressed similar levels of CSE.  Cell lines were much more susceptible to inhibition 
with HA – a dual inhibitor of CBS and CSE – and cell survival was observed to drop 
steeply around 4 mM (140).  Analysis of the flow cytometry plots displaying the 
proportions of apoptotic and necrotic cells reveals that the majority of cell death is due to 
necrosis that occurs following 24 hour treatment with 2-4 mM HA.  Such a sudden 
decline in viability suggests that at this concentration of the CBS/CSE dual inhibitor, 
levels of H2S have declined to a point where the cell can no longer perform essential 
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processes and/or can no longer cope with the oxidative stress being applied.  This is 
supported by the observation that in ccRCC cell lines viability was more severely 
impacted under normoxic conditions when levels of oxidative stress are higher.  
Similarly, others have shown that addition of the antioxidant glutathione can attenuate 
declines in viability seen following loss of H2S production (133). 
4.5 H2S in ccRCC Angiogenesis 
VHL-deficient ccRCC tumours are highly angiogenic as a result of high VEGF secretion 
that is driven by upregulation of both HIF-1α and HIF-2α (17,27).  VEGF secretion has 
been shown to be positively correlated with the size, vascularization, stage and Fuhrman 
grade of ccRCC tumours and has great prognostic value (148).  The efficacy of 
bevacizumab and various RTKIs in the clinical setting speaks to the importance of 
VEGF-mediated angiogenesis in ccRCC progression both prior to and following 
metastasis (11).  Multiple sources of evidence suggest that VEGF-mediated angiogenesis 
is dependent upon tonic inhibition of PDE5 by H2S in endothelial cells (107-109,149).  
Other mechanisms by which H2S exerts its pro-angiogenic effects have also been 
suggested (71,149).  ccRCC xenograft vascularization assays performed here support 
these lines of evidence. 
It was found that the attraction of blood vessels towards VHL-deficient ccRCC 
xenografts could be reduced upon systemic inhibition of endogenous H2S production.  It 
could not be determined whether the intravascularly-injected inhibitor was targeting H2S 
production in endothelial cells or in the cancer cells themselves.  The VHL-deficient 
xenografts were observed to decrease in size following HA treatment which could 
indicate direct cytotoxicity of the treatment, and suggest that H2S production was being 
targeted in the tumour.  However, the decrease in xenograft size could also have been the 
effect of being starved of nutrients that aren’t being supplied due to devascularization, 
which would suggest that treatments failed to reach the tumour are were acting on 
endothelial cells.  Others have shown that chick endothelial cells are susceptible to 
inhibition of endogenous H2S production within the CAM vasculature (71). 
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Interestingly, the vascularization of VHL WT xenografts was shown to not be susceptible 
to inhibition of H2S production.  These cell lines have been shown to secrete lower levels 
of VEGF and were, on average, less well vascularized than their VHL-deficient 
counterparts (26,27).  The VEGF-mediated vascularization of these tumours plays less of 
a role and this is likely why the inhibitor was not effective.  The fact that the inhibitor had 
no effect on the vascularization of xenografts secreting lower levels of VEGF lends 
credence to the role of H2S in VEGF-mediated angiogenesis.  Of further interest, 
systemic treatment with LC resulted in noticeable vessel vasodilation, but only when 
these vessels were in close proximity to VHL-deficient xenografts.  This would suggest 
that the treatments are acting directly on the cancer cells, resulting in changes in tumour-
derived H2S that affects the surrounding vasculature through paracrine signalling. 
4.6 Translational Applications 
In this study, it has been shown that inhibition of endogenous H2S production can target 
multiple aspects of ccRCC disease progression, making it a potentially promising 
treatment option of mRCC.  Depending on the dosage of treatment, the dual CBS/CSE 
inhibitor preferentially targeted the proliferation, metabolism, and survival of ccRCC cell 
lines over non-malignant renal epithelial cells in vitro.  Furthermore, systemic 
intravascular injection of the inhibitor was able to decrease the vascularization of ccRCC 
xenografts without impacting the survival of chick embryos. Some of these effects were 
observed in both VHL WT and VHL-deficient cell lines, and some were observed 
regardless of VHL status.  When translating these findings to the clinical setting, it will 
be important to identify markers that are more predictive of therapeutic efficacy than 
VHL-deficiency seems to be (148).  As was observed in ccRCC cell lines, human ccRCC 
tumours did not display increased expression of H2S-producing enzymes when compared 
to normal tissue, therefore total expression of CBS, CSE and MPST may not be helpful in 
this regard.  However, interesting localization patterns of CBS and CSE were observed in 
ccRCC which could be of prognostic value or provide insight into the role of H2S in 
ccRCC progression. 
While stage IV mRCC has often been the focus when developing new therapies against 
ccRCC, (neo)adjuvant therapies for treatment of stage II and stage III ccRCC have not 
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been a priority (36).  Many of these diseases have a high risk of relapsing within 5 years 
of surgical resection and this contributes heavily to disease mortality (36).  The cellular 
source of cancer relapse is currently unknown, although there is strong evidence to 
suggest that cancer stem cells may be responsible for this relapse in ccRCC and other 
cancers (150).  Recent work has shown that the production of H2S plays a key role in 
maintaining the stem-like phenotype of cancer cells through induction of stem cell factors 
OCT4 and NANOG, and through regulation of cellular energy production and oxidative 
stress (139).  Endogenous H2S production was also associated with the spheroid-forming 
and transdifferentiation potential of cells, which are thought to be important processes in 
disease relapse (139).  Treatment with inhibitors of H2S synthesis either before or after 
nephrectomy might limit the ability of any remaining cancer cells to form new tumours. 
One of the challenges of treating mRCC is its resistance to well-established, cost-
effective, readily-available systemic therapies such as chemotherapy and radiation 
therapy (8).  It has been shown that chemopreventive agents – agents that limit the 
efficacy of chemotherapies – often increase the antioxidative potential of cancer cells 
through increased production of glutathione and NADPH and increased activity of Nrf2 
(151,152).  S-Sulfhydration of Keap1 – a protein that suppresses Nrf2 – has been shown 
to prevent the inhibitory effects that Keap1 has on Nrf2, thus increasing the antioxidative 
response (96).  Additional antioxidative properties of H2S include increased production of 
reduced glutathione and polysulfides (67,115), which may be involved in conferring 
chemoresistance in ovarian cancer (133).  Also, hypoxia-induced radioresistance may be 
mediated by the cytoprotective effects of H2S accumulation under hypoxic conditions 
(134,135).  Together, there is much evidence to support that inhibition of endogenous 
H2S production may enhance conventional forms of systemic therapy and should be 
investigated further. 
While targeted therapies have been shown to improve PFS and ORR of patients afflicted 
with mRCC, durable complete responses remain elusive and therapy resistance remains 
an issue (41,42).  Cancer therapies apply a selective pressure on tumours which may or 
may not affect all cells within a tumour.  Those cells that are more resistant to the applied 
pressure are more likely to survive and proliferate, whereas the cells that are affected by 
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the treatment are removed.  With successive rounds of therapy, the composition of the 
tumour changes such that most of the cells are resistant to the applied pressure, and the 
therapy becomes ineffective.  This process called tumour progression applies to various 
selective pressures – such as hypoxia, nutrient deprivation and oxidative stress – that 
occur naturally as the tumour grows in size and composition (136).  Endogenous 
production of H2S seems to facilitate recovery from these selective pressures that arise 
throughout the course of tumour progression (137,138).  It would be interesting to 
determine whether cells that develop resistance to targeted therapies also produce higher 
levels of H2S.  If so, combining inhibitors of endogenous H2S production with recently 
developed targeted therapies could delay the onset of resistance in mRCC.  Similar 
reasoning suggests that inhibition of endogenous H2S production might be a form of 
therapy that ccRCC tumours are less inclined to develop resistance to, although export of 
the inhibitors by P-glycoprotein remains a possibility (8). 
4.7 Recommendations 
The results of this study have exposed multiple avenues for future research.  First and 
foremost, while the use of a dual CBS/CSE inhibitor has provided valuable information 
regarding the adverse effects of such a drug when used in vitro and in vivo, siRNA- or 
shRNA-mediated knockdown of CBS, CSE and MPST would be more valuable in 
determining the importance of each of these three enzymes.  There are currently no bona 
fide MPST inhibitors, and the dual CBS/CSE inhibitor used here has its limitations (140).  
Generation of cell lines with each of CBS, CSE and MPST knocked out using shRNA 
would be ideal in that it would allow for longer experiments both in vitro and in vivo, 
although knocking out each enzyme in all cell lines investigated here would be quite 
time-consuming.  However, it may be the only way to determine if one of these H2S-
producing enzymes is more important than the others, which can then drive the 
development of specific inhibitors. 
In this study, the elevated level of H2S in VHL-deficient ccRCC cell lines was explained 
by decreased mitochondrial biogenesis and activity.  While reduced mitochondrial 
activity and biogenesis has been observed in ccRCC (153), and it is known that the 
majority of ccRCC tumours are VHL-deficient (1), the mechanisms linking 
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mitochondrial metabolism, loss of VHL function and accumulation of HIF-1/2α are still 
being investigated (55).  Moreover, ccRCC cell lines may exhibit higher levels of 
oxidative phosphorylation than primary ccRCC cells (153).  Establishing a more concrete 
relationship between loss of mitochondrial oxidation, VHL deficiency and accumulation 
of H2S is a priority.  Measurement of H2S in primary ccRCC cells using the intracellular 
fluorescent probe and live-cell imaging would be ideal given the high throughput nature 
of the assay.  DNA, RNA and protein analysis of these primary cells would then allow for 
determination of VHL mutation status, HIF-1/2α expression profiling and metabolic 
profiling, each of which could be correlated against the level of H2S in each sample.  
Treatment of these primary cells with inhibitors of endogenous H2S production and 
subsequent viability, proliferation, and metabolic assays would provide a more 
translational approach than the one used here. 
The CAM angiogenesis assay used here provided good evidence that inhibition of 
endogenous H2S production can reduce microvascular density of ccRCC tumours.  The 
logical next step in investigating the role of H2S in ccRCC vascularization is xenografting 
human cell lines into immune-deficient mice and determining whether similar effects are 
observed.  Furthermore, this more complex mammalian system will provide insight into 
the true adverse effects that systemic inhibition of H2S production has on the host.  
Inhibitors of H2S production have been used to treat subcutaneously-xenografted colon 
cancer tumours in mice, although inhibitors were injected subcutaneously and not 
intravascularly (131).  Given the immunogenic nature of ccRCC (40), and the prominent 
role of H2S in immunology and renal inflammation (78), it would be interesting to 
evaluate how this treatment changes the interaction between the tumour and the host 
immune system.  There are commercially available, mouse-derived renal cancer cell lines 
that would make this possible. 
Mouse models have also been developed to evaluate spontaneous metastasis of renal 
cancer cells after orthotopic implantation within the kidney, which would facilitate 
investigation of the role that H2S plays in metastasis (154).  Prior to investigating the 
involvement of H2S in metastatic progression in vivo, it would be best to first investigate 
the involvement of H2S in ccRCC migration and expression of epithelial-mesenchymal 
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transition (EMT) markers.  H2S has been shown to increase the migration of endothelial 
cells (108) and colon cancer cells (131), and has also been shown to induce expression of 
EMT markers COX-2 and MMP2 in liver cancer cells (155).  Addition of ‘anti-
metastatic’ to the list of anti-tumourigenic properties that this therapy has shown to 
possess would increase the likelihood of its clinical efficacy. 
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5. Conclusions 
From this body of work, the following conclusions can be drawn: 
1. Levels of H2S are increased in ccRCC cell lines lacking a functional copy of the 
VHL tumour suppressor. 
2. Increased levels of H2S in ccRCC cell lines are not due to increased expression of 
the H2S-producing enzymes CBS, CSE and MPST.  Furthermore, these enzymes 
are not upregulated in human ccRCC tumours. 
3. Targeting endogenous H2S production in ccRCC cell lines using inhibitors results 
in decreased cell proliferation, metabolism and survival when compared to non-
malignant renal epithelial cells. 
4. Systemic inhibition of endogenous H2S production in chick embryos can reduce 
the vascularization of VHL-deficient ccRCC xenografts. 
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Appendix A: Human RCC Clinical Data 
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1 F 75 1 2 N 6*5.5*5 5 - 0 
2 M 58 3 2 Y 6*5,5*5 2 - 0 
3 F 59 1 4 Y 12*8*7 5 0 0 
4 M 47 1 3 N 7,5*7*5 5 0 0 
5 F 65 4 3 Y 5*7,8*6 3 - 0 
6 M 79 6 - Y 
2.4*2.1*1.
9 
1 - 0 
7 M 53 1 2 Y 
3,3*2,6*2,
6 
1 - 0 
8 M 69 1 2 N 2,5*2*1,8 1 - 0 
9 M 58 1 2 N 3,7*3,5*3 1 - 0 
10 F 54 9 - - 3,5*2,5 4 - 0 
11 M 61 1 2 Y 3*2,5*2,2 1 - 0 
12 M 63 2 3 N 
1,4*1,2*1,
2 
1 - 0 
13 M 50 2 3 N 3,5*3*3 1 - 0 
14 M 64 7 4 Y 14*12*12 4 - 1 
15 M 61 1 3 N 5,5*5*5,5 4 - 1 
16 M 50 1 3 Y 5*4*3 2 - 0 
17 M 77 1 3 N 7,5*6.5*6 5 - 0 
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18 M 67 3 4 N 4*2,5*2,5 1 - 0 
19 M 63 3 3 Y 
1,4*1,2*1,
1 
1 - 0 
20 F 63 8 1 N 
1,4*1,3*0,
9 
1 - 0 
21 M 80 1 3 Y 4*3,8*3,5 1 - 0 
22 M 66 4 - N 5*4*3,3 2 - 0 
23 M 69 1 3 N 5*4*4 4 - 0 
24 F 68 1 3 N 3*2.5*2 1 - 0 
25 F 38 3 3 N 6.5*4*4 2 - 0 
26 M 66 3 3 N 5*4*3.3 2 - 0 
27 M 50 10 2 N 3*2,5*2 1 - 0 
28 M 78 3 3 Y 8,5*8*8 4 1 0 
29 M 70 6 - N 3,5*3*3 1 - 0 
30 M 77 1 2 N 5*5*4 2 - 0 
31 F 57 1 4 Y 10*10*9 5 - 1 
32 F 70 1 4 Y 7,2*7*5,5 3 - 0 
33 F 63 7 2 N 
2,5*2,5*2,
3 
1 - 0 
34 M 50 4 - N 7,5*7*6 3 - 0 
35 M 69 1 3 N 
1,7*1,6*1,
4 
1 - 0 
36 M 62 1 3 Y 9.5*9*5 4 - 0 
99 
 
P
a
ti
en
t 
#
 
S
ex
 
A
g
e 
a
t 
su
rg
er
y
 
H
is
to
lo
g
ic
a
l 
su
b
ty
p
e*
 
F
u
h
rm
a
n
 
G
ra
d
e 
T
u
m
o
r 
n
ec
ro
si
s 
T
u
m
o
r 
D
im
en
si
o
n
s 
T
 s
ta
g
e*
*
 
N
 s
ta
g
e
 
M
 s
ta
g
e
 
37 F 49 1 4 Y 8*8*5 5 - 1 
38 M 63 3 4 Y 
3.5*3*3 & 
4*4*3.5 
5 - 0 
39 M 57 2 3 N 6,5*5*4 2 - 0 
40 F 62 1 4 N 8*5,5*5 5 0 1 
41 F 58 1 4 N 9*8*7,5 4 - 1 
42 F 50 1 3 N 6*5*5 4 - 0 
43 M 44 4 2 N 8*5,5*6 3 - 0 
44 F 47 5 1 Y 
2,5*2,2*1,
5 
1 - 0 
45 M 59 3 - - -99 - - 0 
46 M 54 1 1 Y 
2,5*2,2*1,
1 
1 - 0 
47 F 45 1 - - 5 2 - 0 
48 M 55 1 3 Y 
8,8*8,5*7,
8 
4 - 0 
49 M 49 1 2 N 2,5*2*2 1 0 0 
50 M 54 1 3 Y 
4,5*3,3*4,
5 
2 - 0 
 
* 1=Clear Cell, 2=Papillary type I, 3=Papillary typeII, 4=Chromophobe, 5=Collecting 
duct, 6=Oncocytoma, 7=unclassified, 8=thyroid-like RCC, 9=Angiomyolipoma, 
10=multilocular cystic RCC 
** 1=T1a, 2=T1b, 3=T2, 4=T3a, 5=T3b, 6=T3c, 7=T4 
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